<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"><channel rdf:about="http://onlinelibrary.wiley.com/rss/journal/10.1111/(ISSN)1440-0960" xmlns="http://purl.org/rss/1.0/"><title>Australasian Journal of Dermatology</title><description> Wiley Online Library : Australasian Journal of Dermatology</description><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2F%28ISSN%291440-0960</link><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc</dc:publisher><dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">en</dc:language><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">© The Australasian College of Dermatologists</dc:rights><prism:issn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">0004-8380</prism:issn><prism:eIssn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1440-0960</prism:eIssn><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-01T00:00:00-05:00</dc:date><prism:coverDisplayDate xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">May 2013</prism:coverDisplayDate><prism:volume xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">54</prism:volume><prism:number xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">2</prism:number><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e28</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e55</prism:endingPage><image rdf:resource="http://onlinelibrary.wiley.com/store/10.1111/ajd.2013.54.issue-2/asset/cover.gif?v=1&amp;s=8be781d3c022162d732059e431b1759dbc76eaca"/><items><rdf:Seq><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12058"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12056"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12055"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12054"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12052"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12057"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12047"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12045"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12042"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12041"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12039"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12038"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12037"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12035"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12034"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12043"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12023"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12032"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12031"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12030"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12025"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12026"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12022"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12017"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12016"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12015"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12013"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12012"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12006"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12005"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12004"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12003"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12002"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12000"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00967.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00966.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00963.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00961.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00960.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00954.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00953.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00952.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00949.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00947.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00945.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00944.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00943.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00942.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00941.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00940.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00939.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00938.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00923.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00921.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00919.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00907.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00904.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00896.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00886.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00873.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00911.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00950.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00968.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12001"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12027"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12028"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12029"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00962.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00937.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00946.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00861.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00866.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00926.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12033"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00936.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12050"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12014"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12060"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00827.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00847.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00826.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00865.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00848.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00857.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00875.x"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00874.x"/></rdf:Seq></items></channel><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12058" xmlns="http://purl.org/rss/1.0/"><title>Reticulated acanthoma with sebaceous differentiation: another sebaceous neoplasm associated with Muir–Torre syndrome?</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12058</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Reticulated acanthoma with sebaceous differentiation: another sebaceous neoplasm associated with Muir–Torre syndrome?</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wonwoo Shon, Michael M Wolz, Catherine C Newman, Alina G Bridges</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-08T03:05:04.101876-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12058</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12058</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12058</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Reticulated acanthoma with sebaceous differentiation (RASD) represents a rare benign cutaneous epithelial neoplasm with sebaceous differentiation. There has been much speculation about the relationship between RASD and Muir–Torre syndrome (MTS). We report a 53 year-old man who presented with RASD in addition to a prior history of sebaceous adenomas. Immunohistochemically, the tumour cells in the RASD and sebaceous adenomas showed a significantly reduced MSH6 protein expression, whereas there was no loss of MLH1, MSH2 and PMS2. This benign neoplasm, which can be mistaken for various other cutaneous lesions with sebaceous differentiation, deserves wider recognition for its possible association with MTS.</p></div>
]]></content:encoded><description>

Reticulated acanthoma with sebaceous differentiation (RASD) represents a rare benign cutaneous epithelial neoplasm with sebaceous differentiation. There has been much speculation about the relationship between RASD and Muir–Torre syndrome (MTS). We report a 53 year-old man who presented with RASD in addition to a prior history of sebaceous adenomas. Immunohistochemically, the tumour cells in the RASD and sebaceous adenomas showed a significantly reduced MSH6 protein expression, whereas there was no loss of MLH1, MSH2 and PMS2. This benign neoplasm, which can be mistaken for various other cutaneous lesions with sebaceous differentiation, deserves wider recognition for its possible association with MTS.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12056" xmlns="http://purl.org/rss/1.0/"><title>Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12056</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jenny Tu, Jonathan Chan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-08T03:04:53.653387-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12056</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12056</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12056</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Biological therapy with tumour necrosis factor alpha antibodies continues to offer a life-changing option for a range of autoimmune and inflammatory skin conditions. We present three cases of sarcoidosis, with refractory cutaneous disease successfully treated with infliximab. A review of the literature shows increased numbers of cases of refractory cutaneous sarcoidosis successfully cleared with infliximab therapy.</p></div>
]]></content:encoded><description>

Biological therapy with tumour necrosis factor alpha antibodies continues to offer a life-changing option for a range of autoimmune and inflammatory skin conditions. We present three cases of sarcoidosis, with refractory cutaneous disease successfully treated with infliximab. A review of the literature shows increased numbers of cases of refractory cutaneous sarcoidosis successfully cleared with infliximab therapy.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12055" xmlns="http://purl.org/rss/1.0/"><title>5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12055</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ben Tallon, Nicholas Turnbull</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-08T03:04:46.019694-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12055</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12055</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12055</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Elderly patients with extensive hypertrophic solar keratoses and squamous cell carcinoma on the lower legs can pose significant management challenges. Typically these patients require surgical treatment which is complicated by comorbidities and poor background lower leg skin. 5% fluorouracil chemowraps provides a useful alternative technique for the management of diffuse hypertrophic solar keratoses and as an adjuvant, and in some situations as a palliative treatment, for squamous cell carcinomas on the lower legs.</p></div>
]]></content:encoded><description>

Elderly patients with extensive hypertrophic solar keratoses and squamous cell carcinoma on the lower legs can pose significant management challenges. Typically these patients require surgical treatment which is complicated by comorbidities and poor background lower leg skin. 5% fluorouracil chemowraps provides a useful alternative technique for the management of diffuse hypertrophic solar keratoses and as an adjuvant, and in some situations as a palliative treatment, for squamous cell carcinomas on the lower legs.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12054" xmlns="http://purl.org/rss/1.0/"><title>Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12054</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lucy J Dang, John S Lubel, Shyamalar Gunatheesan, Patrick Hosking, John Su</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-08T03:04:36.504935-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12054</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12054</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12054</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We describe a case of previously unreported autoimmune hepatitis and lupus-like syndrome induced by infliximab treatment for chronic plaque psoriasis. The condition resolved after withdrawal of infliximab, with the liver injury having been reversed and minimal periportal fibrosis. In a two-part discussion we review the current literature on the pharmacology of infliximab and provide recommendations for management of infliximab side effects.</p></div>
]]></content:encoded><description>

We describe a case of previously unreported autoimmune hepatitis and lupus-like syndrome induced by infliximab treatment for chronic plaque psoriasis. The condition resolved after withdrawal of infliximab, with the liver injury having been reversed and minimal periportal fibrosis. In a two-part discussion we review the current literature on the pharmacology of infliximab and provide recommendations for management of infliximab side effects.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12052" xmlns="http://purl.org/rss/1.0/"><title>Laser photodynamic treatment for in situ squamous cell carcinoma of the glans monitored by reflectance confocal microscopy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12052</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Laser photodynamic treatment for in situ squamous cell carcinoma of the glans monitored by reflectance confocal microscopy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elisa Cinotti, Jean Luc Perrot, Bruno Labeille, Catherine Douchet, Nicolas Mottet, Frédéric Cambazard</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-08T03:04:31.564775-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12052</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12052</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12052</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>While mutilating surgery can be avoided with non-surgical treatment of <em>in situ</em> squamous cell carcinoma (SCC) of the penis, such as photodynamic therapy (PDT), this procedure is not followed by histological evaluation to verify the total removal of the lesion, leading to possible recurrence. We present the first case of <em>in situ</em> penile SCC treated with laser PDT, where the efficacy of the treatment was monitored by reflectance confocal microscopy (RCM) using a handheld camera. In the future RCM may be regarded as a complementary technique to assess the efficacy of non-surgical treatment of mucous membrane cancers.</p></div>
]]></content:encoded><description>

While mutilating surgery can be avoided with non-surgical treatment of in situ squamous cell carcinoma (SCC) of the penis, such as photodynamic therapy (PDT), this procedure is not followed by histological evaluation to verify the total removal of the lesion, leading to possible recurrence. We present the first case of in situ penile SCC treated with laser PDT, where the efficacy of the treatment was monitored by reflectance confocal microscopy (RCM) using a handheld camera. In the future RCM may be regarded as a complementary technique to assess the efficacy of non-surgical treatment of mucous membrane cancers.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12057" xmlns="http://purl.org/rss/1.0/"><title>Ice anaesthesia in procedural dermatology</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12057</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ice anaesthesia in procedural dermatology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shreya Dixit, Patricia Lowe, Gayle Fischer, Adrian Lim</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-26T03:18:53.098249-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12057</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12057</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12057</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Procedural Dermatology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>This article presents findings from a survey of Australian dermatologists who were questioned about their preferred pain control methods when carrying out injectable procedures. We also present, what is to the best of our knowledge, the first proof-of-concept experiment exploring the relationship between ice-to-skin contact time and skin surface temperature, using both ice wrapped in latex and ice wrapped in aluminium foil. Of 79 dermatologists 32 responded to the survey (41% response rate): 31 (97%) injected botulinum toxin type A (BTA) for dynamic lines, 26 (81%) injected BTA for hyperhidrosis, and 24 (75%) injected skin fillers. Ice anaesthesia was the most common method of pain control (75%) followed by use of topical anaesthesia (50%) such as EMLA, compound agents and lignocaine 4%. Ice wrapped in latex or latex-like material was the most common ice packaging used by those surveyed and the median ice-to-skin contact time was 10 s. The ice experiment results indicated that ice wrapped with aluminium foil was equivalent to ice wrapped in latex for short contact times (&lt; 20 s), but more effective at reducing skin temperature with longer contact times (&gt; 20 s). These findings will be of relevance to cosmetic and paediatric dermatologists or any area of procedural medicine where effective non-injectable pain control is required.</p></div>
]]></content:encoded><description>

This article presents findings from a survey of Australian dermatologists who were questioned about their preferred pain control methods when carrying out injectable procedures. We also present, what is to the best of our knowledge, the first proof-of-concept experiment exploring the relationship between ice-to-skin contact time and skin surface temperature, using both ice wrapped in latex and ice wrapped in aluminium foil. Of 79 dermatologists 32 responded to the survey (41% response rate): 31 (97%) injected botulinum toxin type A (BTA) for dynamic lines, 26 (81%) injected BTA for hyperhidrosis, and 24 (75%) injected skin fillers. Ice anaesthesia was the most common method of pain control (75%) followed by use of topical anaesthesia (50%) such as EMLA, compound agents and lignocaine 4%. Ice wrapped in latex or latex-like material was the most common ice packaging used by those surveyed and the median ice-to-skin contact time was 10 s. The ice experiment results indicated that ice wrapped with aluminium foil was equivalent to ice wrapped in latex for short contact times (&lt; 20 s), but more effective at reducing skin temperature with longer contact times (&gt; 20 s). These findings will be of relevance to cosmetic and paediatric dermatologists or any area of procedural medicine where effective non-injectable pain control is required.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12047" xmlns="http://purl.org/rss/1.0/"><title>Mycoplasma pneumoniae: an aetiological agent of acute haemorrhagic oedema of infancy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12047</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Mycoplasma pneumoniae: an aetiological agent of acute haemorrhagic oedema of infancy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vito Di Lernia</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-10T04:30:51.790371-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12047</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12047</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12047</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Acute haemorrhagic oedema of infancy (AHEI) is considered a separate clinical entity among cutaneous small vessel vasculitis of childhood. It usually occurs in children younger than 2 years of age, with spontaneous recovery occurring within a few weeks. A history of recent upper respiratory or urinary tract infections or immunisation is found in most patients. Although <em>Mycoplasma pneumoniae</em> has been linked to a wide array of skin eruptions or diseases, it is not recognised as a possible cause of acute haemorrhagic oedema of infancy. The authors report a child with AHEI and a concurrent <em>M. pneumoniae</em> infection.</p></div>
]]></content:encoded><description>

Acute haemorrhagic oedema of infancy (AHEI) is considered a separate clinical entity among cutaneous small vessel vasculitis of childhood. It usually occurs in children younger than 2 years of age, with spontaneous recovery occurring within a few weeks. A history of recent upper respiratory or urinary tract infections or immunisation is found in most patients. Although Mycoplasma pneumoniae has been linked to a wide array of skin eruptions or diseases, it is not recognised as a possible cause of acute haemorrhagic oedema of infancy. The authors report a child with AHEI and a concurrent M. pneumoniae infection.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12045" xmlns="http://purl.org/rss/1.0/"><title>Clinical and histopathological characteristics of extra-facial basal cell carcinoma: Analysis of 35 patients at the Chonbuk National University Hospital in Korea</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12045</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clinical and histopathological characteristics of extra-facial basal cell carcinoma: Analysis of 35 patients at the Chonbuk National University Hospital in Korea</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Si-Gyun Roh, Jin Park, Ki-Hun Song, Kyung-Hwa Nam, Seok-Kweon Yun, Han-Uk Kim</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-10T04:30:49.928706-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12045</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12045</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12045</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Series</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Basal cell carcinoma (BCC) primarily develops in the head and neck region, with 74–83 per cent of BCC occurring in this region. Unfortunately, most published studies on BCC were conducted in Caucasian populations, and analytic data on extra-facial BCC in Asian and Korean patients, in particular, are not readily available. Here, we report on a retrospective analysis of extra-facial BCC in Korean patients. Thirty-five patients (16 men, 19 women) diagnosed with extra-facial BCC at Chonbuk National University Hospital between January 1981 and December 2008 were evaluated. Their average age was 62.3 years and most of the patients (11 of 35, 31%) were in their fifties. The relative tumour density (RTD) was the highest in the genitalia (0.769), followed by the axilla (0.481). Other regions such as the trunk, buttocks and upper and lower extremities exhibited a much lower RTD (average: 0.1). Histopathological examinations showed that 16 tumours were nodular (46%), eight were superficial (23%) and seven were mixed (20%). Additionally, potential predisposing factors were identified in seven cases. In five patients the use of Asian medicine, including acupuncture and herbal medication, was ascertained. To the best of our knowledge, the present study is the first to analyse the clinical and histopathological characteristics of extra-facial BCC in Korean patients. Our results indicate that the incidence of extra-facial BCC is higher in the axilla and genitalia than at other locations, although these sites are frequently overlooked during routine skin examinations.</p></div>
]]></content:encoded><description>

Basal cell carcinoma (BCC) primarily develops in the head and neck region, with 74–83 per cent of BCC occurring in this region. Unfortunately, most published studies on BCC were conducted in Caucasian populations, and analytic data on extra-facial BCC in Asian and Korean patients, in particular, are not readily available. Here, we report on a retrospective analysis of extra-facial BCC in Korean patients. Thirty-five patients (16 men, 19 women) diagnosed with extra-facial BCC at Chonbuk National University Hospital between January 1981 and December 2008 were evaluated. Their average age was 62.3 years and most of the patients (11 of 35, 31%) were in their fifties. The relative tumour density (RTD) was the highest in the genitalia (0.769), followed by the axilla (0.481). Other regions such as the trunk, buttocks and upper and lower extremities exhibited a much lower RTD (average: 0.1). Histopathological examinations showed that 16 tumours were nodular (46%), eight were superficial (23%) and seven were mixed (20%). Additionally, potential predisposing factors were identified in seven cases. In five patients the use of Asian medicine, including acupuncture and herbal medication, was ascertained. To the best of our knowledge, the present study is the first to analyse the clinical and histopathological characteristics of extra-facial BCC in Korean patients. Our results indicate that the incidence of extra-facial BCC is higher in the axilla and genitalia than at other locations, although these sites are frequently overlooked during routine skin examinations.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12042" xmlns="http://purl.org/rss/1.0/"><title>Mycophenolate use in dermatology: A clinical audit</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12042</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Mycophenolate use in dermatology: A clinical audit</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jane Li, Alvin H Chong, Jack Green, Christopher Baker</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-10T04:30:35.155969-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12042</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12042</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12042</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Series</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Mycophenolate use in dermatology is growing due to its reputation as a steroid-sparing agent with a favourable side-effect profile. However, there are limited data on the efficacy and tolerability of mycophenolate for many dermatological indications. We conducted a retrospective clinical audit in 33 dermatology patients who had received mycophenolate at our institution between April 2010 and January 2012. The top indication was pyoderma gangrenosum (14 patients) followed by atopic dermatitis (seven patients). Overall 70 per cent of patients showed some benefit from mycophenolate treatment, with 12 per cent failing to respond. Side-effects were experienced by 45 per cent of patients, two of whom had serious side-effects. Female sex appears to be a risk factor for adverse effects. We conclude that although mycophenolate is a promising agent across a variety of dermatological conditions, further randomised controlled trials are required.</p></div>
]]></content:encoded><description>

Mycophenolate use in dermatology is growing due to its reputation as a steroid-sparing agent with a favourable side-effect profile. However, there are limited data on the efficacy and tolerability of mycophenolate for many dermatological indications. We conducted a retrospective clinical audit in 33 dermatology patients who had received mycophenolate at our institution between April 2010 and January 2012. The top indication was pyoderma gangrenosum (14 patients) followed by atopic dermatitis (seven patients). Overall 70 per cent of patients showed some benefit from mycophenolate treatment, with 12 per cent failing to respond. Side-effects were experienced by 45 per cent of patients, two of whom had serious side-effects. Female sex appears to be a risk factor for adverse effects. We conclude that although mycophenolate is a promising agent across a variety of dermatological conditions, further randomised controlled trials are required.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12041" xmlns="http://purl.org/rss/1.0/"><title>Periorbital allergic contact dermatitis resulting from topical retinoic acid use</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12041</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Periorbital allergic contact dermatitis resulting from topical retinoic acid use</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Austen Anderson, Kurt Gebauer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-10T04:30:21.666211-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12041</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12041</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12041</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Contact dermatitis to topical tretinoin or retinoic acid is rarely described. We outline the case of a 20-year-old woman presenting with bilateral periorbital dermatitis against the background of longstanding use of retinoic acid for the ocular complications of toxic epidermal necrolysis. Patch testing confirmed a contact allergy to retinoic acid and the symptoms of the dermatitis resolved after the cessation of retinoic acid.</p></div>
]]></content:encoded><description>

Contact dermatitis to topical tretinoin or retinoic acid is rarely described. We outline the case of a 20-year-old woman presenting with bilateral periorbital dermatitis against the background of longstanding use of retinoic acid for the ocular complications of toxic epidermal necrolysis. Patch testing confirmed a contact allergy to retinoic acid and the symptoms of the dermatitis resolved after the cessation of retinoic acid.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12039" xmlns="http://purl.org/rss/1.0/"><title>Redefining the number needed to excise</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12039</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Redefining the number needed to excise</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lucy Chen, Stephen Dusza, Marta Grazzini, Andreas Blum, Ashfaq Marghoob</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-10T04:28:34.047183-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12039</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12039</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12039</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The number needed to excise (NNE) is a metric used to convey the efficiency of dermatological practice by serving as a gauge for the diagnostic accuracy of melanoma. Rather than an NNE for melanoma alone, we assert that the NNE should measure all skin cancer types and we present data on NNE from two clinical sites demonstrating the utility and trends in NNE over time.</p></div>
]]></content:encoded><description>

The number needed to excise (NNE) is a metric used to convey the efficiency of dermatological practice by serving as a gauge for the diagnostic accuracy of melanoma. Rather than an NNE for melanoma alone, we assert that the NNE should measure all skin cancer types and we present data on NNE from two clinical sites demonstrating the utility and trends in NNE over time.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12038" xmlns="http://purl.org/rss/1.0/"><title>Diet-induced pigmented purpuric dermatosis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12038</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Diet-induced pigmented purpuric dermatosis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Katharina T. Weiß, Sigrid Karrer, Michael Landthaler, Philipp Babilas, Stephan Schreml</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-10T04:28:31.653288-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12038</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12038</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12038</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Pigmented purpuric dermatoses (PPD) are chronic and relapsing disorders characterised by a localised or generalised purpuric rash. Even though the clinical presentation of PPD subtypes varies, they have a similar histopathology. The aetiology is largely unknown, but trigger factors, such as drugs, infections and systemic illnesses have been described. To our knowledge, this is the only case showing widespread PPD lesions not only induced but also rapidly provoked by dietary factors, namely Coca Cola and apple-cherry fruit spritzer.</p></div>
]]></content:encoded><description>

Pigmented purpuric dermatoses (PPD) are chronic and relapsing disorders characterised by a localised or generalised purpuric rash. Even though the clinical presentation of PPD subtypes varies, they have a similar histopathology. The aetiology is largely unknown, but trigger factors, such as drugs, infections and systemic illnesses have been described. To our knowledge, this is the only case showing widespread PPD lesions not only induced but also rapidly provoked by dietary factors, namely Coca Cola and apple-cherry fruit spritzer.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12037" xmlns="http://purl.org/rss/1.0/"><title>TEN-like eruption in setting of EBV positive T-cell lymphoproliferative disease with HLH, in a child</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12037</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">TEN-like eruption in setting of EBV positive T-cell lymphoproliferative disease with HLH, in a child</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Niyati Sharma, Jonathan Clark, Hiep Pham, Daryl Efron, Duncan MacGregor, Rodney O'Keefe, David Orchard</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-10T04:28:29.470879-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12037</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12037</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12037</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Haemophagocytic lymphohistiocytosis complicating Epstein–Barr virus positive T-cell lymphoproliferative disease of childhood is a rare and life-threatening entity. We report a child with this condition presenting with a toxic epidermal necrolysis-like eruption.</p></div>
]]></content:encoded><description>

Haemophagocytic lymphohistiocytosis complicating Epstein–Barr virus positive T-cell lymphoproliferative disease of childhood is a rare and life-threatening entity. We report a child with this condition presenting with a toxic epidermal necrolysis-like eruption.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12035" xmlns="http://purl.org/rss/1.0/"><title>Malignant change in seborrhoeic keratoses in a region with high solar ultraviolet levels</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12035</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Malignant change in seborrhoeic keratoses in a region with high solar ultraviolet levels</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel C Gaffney, James B Muir, Brian De'Ambrosis</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-10T04:28:26.006788-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12035</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12035</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12035</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Regions with high solar UV levels and high skin cancer rates may experience a greater incidence of malignancy in association with seborrhoeic keratoses (SebK) than in low UV regions. Previous reports have indicated that basal cell carcinoma is the most common neoplasm with reported rates of up to 4 per cent of excised SebK. The rates of such compound lesions occurring in our practice were reviewed, indicating that Bowen's disease was the most frequently observed neoplasm with a rate of 7 per cent. In total, 10 per cent of all excised specimens showed either frank malignancy or some degree of atypia.</p></div>
]]></content:encoded><description>

Regions with high solar UV levels and high skin cancer rates may experience a greater incidence of malignancy in association with seborrhoeic keratoses (SebK) than in low UV regions. Previous reports have indicated that basal cell carcinoma is the most common neoplasm with reported rates of up to 4 per cent of excised SebK. The rates of such compound lesions occurring in our practice were reviewed, indicating that Bowen's disease was the most frequently observed neoplasm with a rate of 7 per cent. In total, 10 per cent of all excised specimens showed either frank malignancy or some degree of atypia.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12034" xmlns="http://purl.org/rss/1.0/"><title>Lasers and laser-like devices: Part one</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12034</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Lasers and laser-like devices: Part one</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicholas Stewart, Adrian C Lim, Patricia M Lowe, Greg Goodman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-10T04:27:32.617003-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12034</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12034</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12034</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Lasers have been used in dermatology for nearly 50 years. Through their selective targeting of skin chromophores they have become the preferred treatment for many skin conditions, including vascular malformations, photorejuvenation and acne scars. The technology and design of lasers continue to evolve, allowing greater control of laser parameters and resulting in increased safety and efficacy for patients. Innovations have allowed the range of conditions and the skin types amenable to treatment, in both general and cosmetic dermatology, to expand over the last decade. Integrated skin cooling and laser beam fractionation, for example, have improved safety, patient tolerance and decreased downtime. Furthermore, the availability and affordability of quality devices continues to increase, allowing clinicians not only to access laser therapies more readily but also to develop their personal experience in this field. As a result, most Australian dermatologists now have access to laser therapies, either in their own practice or within referable proximity, and practical knowledge of these technologies is increasingly required and expected by patients. Non-laser energy devices utilising intense pulsed light, plasma, radiofrequency, ultrasound and cryolipolysis contribute to the modern laser practitioners' armamentarium and will also be discussed.</p></div>
]]></content:encoded><description>

Lasers have been used in dermatology for nearly 50 years. Through their selective targeting of skin chromophores they have become the preferred treatment for many skin conditions, including vascular malformations, photorejuvenation and acne scars. The technology and design of lasers continue to evolve, allowing greater control of laser parameters and resulting in increased safety and efficacy for patients. Innovations have allowed the range of conditions and the skin types amenable to treatment, in both general and cosmetic dermatology, to expand over the last decade. Integrated skin cooling and laser beam fractionation, for example, have improved safety, patient tolerance and decreased downtime. Furthermore, the availability and affordability of quality devices continues to increase, allowing clinicians not only to access laser therapies more readily but also to develop their personal experience in this field. As a result, most Australian dermatologists now have access to laser therapies, either in their own practice or within referable proximity, and practical knowledge of these technologies is increasingly required and expected by patients. Non-laser energy devices utilising intense pulsed light, plasma, radiofrequency, ultrasound and cryolipolysis contribute to the modern laser practitioners' armamentarium and will also be discussed.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12043" xmlns="http://purl.org/rss/1.0/"><title>First case report of Nocardia veterana causing nodular lymphangitis in an immunocompromised host</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12043</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">First case report of Nocardia veterana causing nodular lymphangitis in an immunocompromised host</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Janet Dua, Rima Clayton</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-08T20:37:56.913121-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12043</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12043</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12043</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We report a unique case of ascending cutaneous lymphangitis in a 72-year-old immunocompromised man from which a newly described <em>Nocardia</em> species was isolated by 16S ribosomal gene sequencing. Treatment with trimethoprim-sulfamethoxazole resulted in successful resolution of symptoms. To the best of our knowledge, this is the first case report of <em>N. veterana</em> implicated in causing ascending cutaneous lymphangitis.</p></div>
]]></content:encoded><description>

We report a unique case of ascending cutaneous lymphangitis in a 72-year-old immunocompromised man from which a newly described Nocardia species was isolated by 16S ribosomal gene sequencing. Treatment with trimethoprim-sulfamethoxazole resulted in successful resolution of symptoms. To the best of our knowledge, this is the first case report of N. veterana implicated in causing ascending cutaneous lymphangitis.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12023" xmlns="http://purl.org/rss/1.0/"><title>Clinically verrucous and histologically discohesive melanoma. A case report with dermoscopic and immunohistochemical observations</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12023</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clinically verrucous and histologically discohesive melanoma. A case report with dermoscopic and immunohistochemical observations</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takamitsu Ohnishi, Maki Hamano, Shinichi Watanabe</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-27T02:56:49.953041-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12023</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12023</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12023</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Dermoscopy</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12032" xmlns="http://purl.org/rss/1.0/"><title>Hypomelanosis of Ito and multiple naevoid hypertrichosis: Rare cutaneous mosaicism</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12032</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Hypomelanosis of Ito and multiple naevoid hypertrichosis: Rare cutaneous mosaicism</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ananta Khurana, Archana Singal, Deepika Pandhi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T00:50:16.754581-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12032</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12032</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12032</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Hypomelanosis of Ito and naevoid hypertrichosis are both uncommon disorders and their coexistence in the same patient is rarely described. Most previously reported patients, in addition to cutaneous lesions, had multiple neurological, musculoskeletal and other organ system involvements. We present the case of a 3-year-old girl with these two naevoid disorders at sites completely exclusive of each other and without any severe associated defects.</p></div>
]]></content:encoded><description>

Hypomelanosis of Ito and naevoid hypertrichosis are both uncommon disorders and their coexistence in the same patient is rarely described. Most previously reported patients, in addition to cutaneous lesions, had multiple neurological, musculoskeletal and other organ system involvements. We present the case of a 3-year-old girl with these two naevoid disorders at sites completely exclusive of each other and without any severe associated defects.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12031" xmlns="http://purl.org/rss/1.0/"><title>Dermoscopic features of polypoid epidermal cyst</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12031</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Dermoscopic features of polypoid epidermal cyst</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takamichi Ito, Yuichi Yoshida, Masutaka Furue, Osamu Yamamoto</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T00:49:59.266624-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12031</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12031</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12031</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Dermoscopy</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12030" xmlns="http://purl.org/rss/1.0/"><title>Noninvasive methods for the assessment of photoageing</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12030</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Noninvasive methods for the assessment of photoageing</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laura Wheller, Lynlee L Lin, Eric Chai, Sudipta Sinnya, H Peter Soyer, Tarl W Prow</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T00:49:56.21677-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12030</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12030</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12030</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Small Case Series</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Although histopathological dermal elastosis is the current gold standard for the diagnosis of photoageing, noninvasive methods for quantifying the amount of photodamage to skin are clearly preferable. This study is the first to survey five noninvasive methods of assessing photoageing (clinical examination, spectrophotometry, skin surface topography, reflectance confocal microscopy and fluorescence lifetime imaging microscopy) in the same individual. Measurements for each noninvasive method were compared across nine individuals from three participant groups (‘younger’, ‘older’ and ‘photodamaged’) in UV-protected volar and UV-exposed dorsal forearm skin. Overall, participants in the younger group had the lowest measures of photodamage, while those in the photodamaged group had the highest, as indicated by each modality. The five noninvasive strategies surveyed in this study may demonstrate potential as a suitable methodology for the quantification of photoageing. The advantage of such noninvasive methods is that they allow for skin visualisation <em>in vivo</em> and repeated assessments of the same site. The main limitation of this study was its small sample size, which may have precluded many findings of statistical significance.</p></div>
]]></content:encoded><description>

Although histopathological dermal elastosis is the current gold standard for the diagnosis of photoageing, noninvasive methods for quantifying the amount of photodamage to skin are clearly preferable. This study is the first to survey five noninvasive methods of assessing photoageing (clinical examination, spectrophotometry, skin surface topography, reflectance confocal microscopy and fluorescence lifetime imaging microscopy) in the same individual. Measurements for each noninvasive method were compared across nine individuals from three participant groups (‘younger’, ‘older’ and ‘photodamaged’) in UV-protected volar and UV-exposed dorsal forearm skin. Overall, participants in the younger group had the lowest measures of photodamage, while those in the photodamaged group had the highest, as indicated by each modality. The five noninvasive strategies surveyed in this study may demonstrate potential as a suitable methodology for the quantification of photoageing. The advantage of such noninvasive methods is that they allow for skin visualisation in vivo and repeated assessments of the same site. The main limitation of this study was its small sample size, which may have precluded many findings of statistical significance.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12025" xmlns="http://purl.org/rss/1.0/"><title>The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12025</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel C Gaffney, H Peter Soyer, Fiona Simpson</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T00:47:23.530607-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12025</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12025</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12025</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Squamous cell carcinoma (SCC) of the skin is an increasingly common diagnosis worldwide. Together with precursor lesions, SCC carry a significant morbidity, particularly in regions with high solar UV radiation levels. Advanced lesions are locally or sometimes widely metastatic and may be resistant to treatment. Drugs targeting the epidermal growth factor receptor (EGFR) are currently the only significant non-surgical option for advanced SCC beyond radiotherapy and conventional chemotherapy. The role of the EGFR in skin cancer is described and the outcomes of targeted anti-EGFR therapy published to date are summarised. The future of anti-EGFR targeted therapies in the treatment of skin cancer is discussed. Targeted molecular therapies are becoming increasingly widespread and an understanding of the evidence for their use as well as their side effect profile is important in order to offer patients informed and current advice.</p></div>
]]></content:encoded><description>

Squamous cell carcinoma (SCC) of the skin is an increasingly common diagnosis worldwide. Together with precursor lesions, SCC carry a significant morbidity, particularly in regions with high solar UV radiation levels. Advanced lesions are locally or sometimes widely metastatic and may be resistant to treatment. Drugs targeting the epidermal growth factor receptor (EGFR) are currently the only significant non-surgical option for advanced SCC beyond radiotherapy and conventional chemotherapy. The role of the EGFR in skin cancer is described and the outcomes of targeted anti-EGFR therapy published to date are summarised. The future of anti-EGFR targeted therapies in the treatment of skin cancer is discussed. Targeted molecular therapies are becoming increasingly widespread and an understanding of the evidence for their use as well as their side effect profile is important in order to offer patients informed and current advice.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12026" xmlns="http://purl.org/rss/1.0/"><title>Effective treatment of uremic pruritus and acquired perforating dermatosis with amitriptyline</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12026</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effective treatment of uremic pruritus and acquired perforating dermatosis with amitriptyline</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Angeline Yong, Wei-Sheng Chong, Hong Liang Tey</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T00:47:18.405002-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12026</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12026</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12026</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Generalised pruritus and acquired perforating dermatosis occurring in chronic kidney disease are not uncommon and are often debilitating. However, treatment options are limited. We present two patients with uremic pruritus and acquired perforating dermatosis who were successfully treated with amitriptyline.</p></div>
]]></content:encoded><description>

Generalised pruritus and acquired perforating dermatosis occurring in chronic kidney disease are not uncommon and are often debilitating. However, treatment options are limited. We present two patients with uremic pruritus and acquired perforating dermatosis who were successfully treated with amitriptyline.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12022" xmlns="http://purl.org/rss/1.0/"><title>A clinically invisible melanoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12022</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A clinically invisible melanoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eshini Perera, Nicholas Mellick, Paul Teng, Graeme Beardmore</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T00:47:11.128318-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12022</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12022</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12022</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We report a case of an amelanotic lentigo maligna incidentally found on a shave biopsy in an 87-year-old woman. Amelanotic lentigo maligna is a rare variant of lentigo maligna. It is often reported as presenting as erythematous scaly macules and is usually confused as benign dermatoses. Here were present a case of amelanotic lentigo maligna with no visible or palpable features.</p></div>
]]></content:encoded><description>

We report a case of an amelanotic lentigo maligna incidentally found on a shave biopsy in an 87-year-old woman. Amelanotic lentigo maligna is a rare variant of lentigo maligna. It is often reported as presenting as erythematous scaly macules and is usually confused as benign dermatoses. Here were present a case of amelanotic lentigo maligna with no visible or palpable features.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12017" xmlns="http://purl.org/rss/1.0/"><title>Proliferative nodules of undifferentiated spindle cells arising in a large congenital melanocytic naevus</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12017</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Proliferative nodules of undifferentiated spindle cells arising in a large congenital melanocytic naevus</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elizabeth M Christou, Andrew Chih-Chieh Chen, Ella Sugo, Draga Barbaric, Orli Wargon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-18T01:11:38.504072-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12017</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12017</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12017</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Proliferative nodules (PN) are benign lesions that arise in large congenital melanocytic naevi (LCMN). Clinically and histologically they can be difficult to differentiate from malignancies, which are also associated with LCMN. The PN in this case consisted of undifferentiated spindle cells and exhibited unusual histological features including negative stains for melanocytic markers (S100, HMB45 and MelA), negative stain for c-Kit, high mitotic index and unusual morphology of the lesional cells. As a result, a firm histological classification could not be made, which posed a challenge for the clinical management.</p></div>
]]></content:encoded><description>

Proliferative nodules (PN) are benign lesions that arise in large congenital melanocytic naevi (LCMN). Clinically and histologically they can be difficult to differentiate from malignancies, which are also associated with LCMN. The PN in this case consisted of undifferentiated spindle cells and exhibited unusual histological features including negative stains for melanocytic markers (S100, HMB45 and MelA), negative stain for c-Kit, high mitotic index and unusual morphology of the lesional cells. As a result, a firm histological classification could not be made, which posed a challenge for the clinical management.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12016" xmlns="http://purl.org/rss/1.0/"><title>Cerebral vasculitis and multi-focal neurological deficits due to allopurinol-induced hypersensitivity syndrome</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12016</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cerebral vasculitis and multi-focal neurological deficits due to allopurinol-induced hypersensitivity syndrome</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Lim, Marius Rademaker, Fredrik Asztely, Manjula Ratnaweera, Glenn Coltman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-18T01:11:36.508135-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12016</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12016</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12016</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Drug-induced hypersensitivity syndrome (DIHS) is a multi-system syndrome resulting from an idiosyncratic reaction to medication. While it commonly results in multi-organ involvement, particularly the liver, there are few reports of DIHS causing cerebral vasculitis and neurological deficits. We report the case of a 63-year old woman with DIHS secondary to allopurinol leading to multiple neurological deficits with magnetic resonance imaging findings consistent with a cerebral vasculitis.</p></div>
]]></content:encoded><description>

Drug-induced hypersensitivity syndrome (DIHS) is a multi-system syndrome resulting from an idiosyncratic reaction to medication. While it commonly results in multi-organ involvement, particularly the liver, there are few reports of DIHS causing cerebral vasculitis and neurological deficits. We report the case of a 63-year old woman with DIHS secondary to allopurinol leading to multiple neurological deficits with magnetic resonance imaging findings consistent with a cerebral vasculitis.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12015" xmlns="http://purl.org/rss/1.0/"><title>Use of bleach baths for the treatment of infected atopic eczema</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12015</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Use of bleach baths for the treatment of infected atopic eczema</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tanya M Barnes, Kerryn A Greive</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-18T01:11:31.245888-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12015</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12015</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12015</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Atopic eczema is one of the most common skin disorders in young children and also affects adults. <em>Staphylococcus aureus</em> infection is the most frequent complication of atopic eczema and is involved in the worsening of the disease. Antibiotic therapy against <em>S. aureus</em> has been an important component of treatment for atopic eczema but there are concerns about antibiotic overuse and increasing bacterial resistance. This has led some clinicians to recommend the use of homemade remedies such as bleach baths as an adjunctive treatment for patients with infected atopic eczema, despite the fact that there have been few published studies in this area. Balancing safety concerns with efficacious treatment is of particular importance in the paediatric population. This review discusses the historical use of bleach in medicine as well as its recent use for atopic eczema. Further, the chemistry and safety of bleach as well as alternative therapies are examined.</p></div>
]]></content:encoded><description>

Atopic eczema is one of the most common skin disorders in young children and also affects adults. Staphylococcus aureus infection is the most frequent complication of atopic eczema and is involved in the worsening of the disease. Antibiotic therapy against S. aureus has been an important component of treatment for atopic eczema but there are concerns about antibiotic overuse and increasing bacterial resistance. This has led some clinicians to recommend the use of homemade remedies such as bleach baths as an adjunctive treatment for patients with infected atopic eczema, despite the fact that there have been few published studies in this area. Balancing safety concerns with efficacious treatment is of particular importance in the paediatric population. This review discusses the historical use of bleach in medicine as well as its recent use for atopic eczema. Further, the chemistry and safety of bleach as well as alternative therapies are examined.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12013" xmlns="http://purl.org/rss/1.0/"><title>Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12013</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jazlyn Read</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-18T01:11:26.326782-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12013</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12013</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12013</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Melanoma is an aggressive disease process, with a heterogeneous aetiology linked to environmental and genetic risk factor profiles. Overall prognosis for advanced disease remains poor, and a lack of effective systemic therapies has prompted investigation into alternative strategies. The identification of novel mutations that instigate and perpetuate melanocyte transformation has offered insight into new treatment approaches, and the subsequent development of targeted treatments appears to be integral to improving melanoma survival. This article reviews the mechanisms of melanoma oncogenesis and classic molecular signalling pathways, targeted treatment approaches based on the molecular model and immunotherapy, and the advent of next-generation sequencing technologies in understanding the complexity of the melanoma pathogenome. In addition to the known somatic activating mutations <em>BRAF</em> and <em>NRAS</em>, exome sequencing has recently identified <em>RAC1</em>, a novel UV-signature gain-of-function mutation. Germline mutations associated with familial melanoma have added a further dimension to the molecular underpinnings of melanoma, implicating <em>BAP1</em> and <em>MITF</em> as melanoma predisposition genes. Advances in understanding melanoma and implementing targeted treatment strategies will be of increasing importance in this era of personalised medicine.</p></div>
]]></content:encoded><description>

Melanoma is an aggressive disease process, with a heterogeneous aetiology linked to environmental and genetic risk factor profiles. Overall prognosis for advanced disease remains poor, and a lack of effective systemic therapies has prompted investigation into alternative strategies. The identification of novel mutations that instigate and perpetuate melanocyte transformation has offered insight into new treatment approaches, and the subsequent development of targeted treatments appears to be integral to improving melanoma survival. This article reviews the mechanisms of melanoma oncogenesis and classic molecular signalling pathways, targeted treatment approaches based on the molecular model and immunotherapy, and the advent of next-generation sequencing technologies in understanding the complexity of the melanoma pathogenome. In addition to the known somatic activating mutations BRAF and NRAS, exome sequencing has recently identified RAC1, a novel UV-signature gain-of-function mutation. Germline mutations associated with familial melanoma have added a further dimension to the molecular underpinnings of melanoma, implicating BAP1 and MITF as melanoma predisposition genes. Advances in understanding melanoma and implementing targeted treatment strategies will be of increasing importance in this era of personalised medicine.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12012" xmlns="http://purl.org/rss/1.0/"><title>Trichodysplasia spinulosa: A benign adnexal proliferation with follicular differentiation associated with polyomavirus</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12012</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Trichodysplasia spinulosa: A benign adnexal proliferation with follicular differentiation associated with polyomavirus</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yvonne Y Lee, Simon C Tucker, Natalie A Prow, Yin Xiang Setoh, Leith A Banney</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-18T01:11:20.768609-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12012</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12012</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12012</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Trichodysplasia spinulosa is a rare polyomavirus-associated cutaneous eruption occurring in the setting of immunosuppression. Clinically it is characterised by multiple centrofacial folliculocentric papules with spinous protuberances. The histopathology is distinct and treatment with antiviral agents appears to be the most effective.</p></div>
]]></content:encoded><description>

Trichodysplasia spinulosa is a rare polyomavirus-associated cutaneous eruption occurring in the setting of immunosuppression. Clinically it is characterised by multiple centrofacial folliculocentric papules with spinous protuberances. The histopathology is distinct and treatment with antiviral agents appears to be the most effective.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12006" xmlns="http://purl.org/rss/1.0/"><title>Yellow globules in balloon cell naevus</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12006</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Yellow globules in balloon cell naevus</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elisa Cinotti, Jean Luc Perrot, Bruno Labeille, Catherine Douchet, Gilles Thuret, Frédéric Cambazard</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-29T03:51:44.765273-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12006</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12006</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12006</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Dermoscopy</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12005" xmlns="http://purl.org/rss/1.0/"><title>Male frontal fibrosing alopecia with generalised hair loss</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12005</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Male frontal fibrosing alopecia with generalised hair loss</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">WenChieh Chen, Evanthia Kigitsidou, Hanna Prucha, Johannes Ring, Christian Andres</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-29T03:51:11.655395-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12005</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12005</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12005</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Frontal fibrosing alopecia predominantly affects postmenopausal women and is regarded as a variant of lichen planopilaris. Male cases have rarely been reported. Here we describe a 66-year-old man with a typical receding fronto-temporal hair line in a form of scarring alopecia, which shows features of lichen planopilaris in histology. An extensive loss of body hair involving bilateral axillae, limbs and pubic area was also observed.</p></div>
]]></content:encoded><description>

Frontal fibrosing alopecia predominantly affects postmenopausal women and is regarded as a variant of lichen planopilaris. Male cases have rarely been reported. Here we describe a 66-year-old man with a typical receding fronto-temporal hair line in a form of scarring alopecia, which shows features of lichen planopilaris in histology. An extensive loss of body hair involving bilateral axillae, limbs and pubic area was also observed.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12004" xmlns="http://purl.org/rss/1.0/"><title>Face-masks for facial atopic eczema: Consider a hydrocolloid dressing</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12004</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Face-masks for facial atopic eczema: Consider a hydrocolloid dressing</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marius Rademaker</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-29T03:50:59.331451-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12004</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12004</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12004</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Facial involvement of atopic eczema in young children can be difficult to manage. Chronic scratching and rubbing, combined with parental reluctance to use topical corticosteroids on the face, often results in recalcitrant facial eczema. While wet wraps are a useful management option for moderate/severe atopic eczema involving the trunk and limbs they are difficult to use on the face. We describe the use of a face-mask using a widely available adhesive hydrocolloid dressing (DuoDerm extra thin) in three children with recalcitrant facial atopic eczema. Symptomatic control of itch or soreness was obtained within hours and the facial atopic eczema was markedly improved by 7 days. The face-masks were easy to apply, each lasting 1–4 days. One patient had a single adjuvant application of a potent topical corticosteroid under the hydrocolloid dressing. All three patients had long remissions (greater than 3 months) of their facial eczema, although all continued to have significant eczema involving their trunk and limbs. Face-masks made from hydrocolloid dressings, with or without topical corticosteroids, are worth considering in children with recalcitrant facial eczema.</p></div>
]]></content:encoded><description>

Facial involvement of atopic eczema in young children can be difficult to manage. Chronic scratching and rubbing, combined with parental reluctance to use topical corticosteroids on the face, often results in recalcitrant facial eczema. While wet wraps are a useful management option for moderate/severe atopic eczema involving the trunk and limbs they are difficult to use on the face. We describe the use of a face-mask using a widely available adhesive hydrocolloid dressing (DuoDerm extra thin) in three children with recalcitrant facial atopic eczema. Symptomatic control of itch or soreness was obtained within hours and the facial atopic eczema was markedly improved by 7 days. The face-masks were easy to apply, each lasting 1–4 days. One patient had a single adjuvant application of a potent topical corticosteroid under the hydrocolloid dressing. All three patients had long remissions (greater than 3 months) of their facial eczema, although all continued to have significant eczema involving their trunk and limbs. Face-masks made from hydrocolloid dressings, with or without topical corticosteroids, are worth considering in children with recalcitrant facial eczema.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12003" xmlns="http://purl.org/rss/1.0/"><title>Pigmented purpura dermatosis and viral hepatitis: a case-control study</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12003</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pigmented purpura dermatosis and viral hepatitis: a case-control study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amir H Ehsani, Seyedeh Z Ghodsi, Perdram Nourmohammad-Pour, Nessa Aghazadeh, Maede R Damavandi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-29T03:50:47.451136-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12003</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12003</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12003</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Series</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Pigmented purpuric dermatosis (PPD) is characterized by petechial and pigmented macules on the lower limbs. The aetiology of PPD remains obscure. Some reports have suggested an association between PPD and hepatitis B or C infection. This prospective case-control study was designed to investigate the association of positive hepatitis B or C serology with PPD. A total of 60 PPD patients and 230 randomly selected controls were enrolled. Sera from all patients and controls were tested for liver function tests (LFT), hepatitis B surface antigen (HBS Ag), and hepatitis C virus antibody (HCV Ab). The prevalence of HBS Ag in patients with PPD and the controls was 3 per cent (5/60) and 4.3 per cent (10/230), respectively. The prevalence of HCV Ab was 1.7 per cent (1/60) and 1.3 per cent (3/230) among patients and controls, respectively. No statistically significant difference was noted in the prevalence of positive hepatitis B or C serology (<em>P</em>-values 0.73 and 0.58, respectively). No statistically significant difference in LFT was observed between the two groups. Therefore, the authors believe it is unlikely that HBV or HCV are directly involved in the pathogenesis of PPD.</p></div>
]]></content:encoded><description>

Pigmented purpuric dermatosis (PPD) is characterized by petechial and pigmented macules on the lower limbs. The aetiology of PPD remains obscure. Some reports have suggested an association between PPD and hepatitis B or C infection. This prospective case-control study was designed to investigate the association of positive hepatitis B or C serology with PPD. A total of 60 PPD patients and 230 randomly selected controls were enrolled. Sera from all patients and controls were tested for liver function tests (LFT), hepatitis B surface antigen (HBS Ag), and hepatitis C virus antibody (HCV Ab). The prevalence of HBS Ag in patients with PPD and the controls was 3 per cent (5/60) and 4.3 per cent (10/230), respectively. The prevalence of HCV Ab was 1.7 per cent (1/60) and 1.3 per cent (3/230) among patients and controls, respectively. No statistically significant difference was noted in the prevalence of positive hepatitis B or C serology (P-values 0.73 and 0.58, respectively). No statistically significant difference in LFT was observed between the two groups. Therefore, the authors believe it is unlikely that HBV or HCV are directly involved in the pathogenesis of PPD.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12002" xmlns="http://purl.org/rss/1.0/"><title>Exacerbation of lymphomatoid papulosis during rituximab therapy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12002</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Exacerbation of lymphomatoid papulosis during rituximab therapy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Olivia McCurdy, Chris McCormack, David Ritchie, H. Miles Prince</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-29T03:49:59.5749-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12002</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12002</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12002</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We report two cases of lymphomatoid papulosis (LyP) occurring in conjunction with B-cell lymphoproliferative malignancies where the LyP was exacerbated during rituximab (anti-CD20 antibody)-based therapy. We postulate that the altered B-cell cytokine milieu acted to allow an exacerbation of the patient's concomitant T-cell disease and discuss the possible mechanisms by which this may have occurred.</p></div>
]]></content:encoded><description>

We report two cases of lymphomatoid papulosis (LyP) occurring in conjunction with B-cell lymphoproliferative malignancies where the LyP was exacerbated during rituximab (anti-CD20 antibody)-based therapy. We postulate that the altered B-cell cytokine milieu acted to allow an exacerbation of the patient's concomitant T-cell disease and discuss the possible mechanisms by which this may have occurred.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12000" xmlns="http://purl.org/rss/1.0/"><title>CD25+ folliculotropic Sézary syndrome with CD30+ large cell transformation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12000</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">CD25+ folliculotropic Sézary syndrome with CD30+ large cell transformation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Min Soo Jang, Dong Young Kang, Sang Hwa Han, Jong Bin Park, Sang Tae Kim, Kee Suck Suh</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-29T03:49:45.36801-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12000</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12000</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12000</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Folliculotropic Sézary syndrome is a rare and unique variant of cutaneous T-cell lymphoma (CTCL) characterised by both follicular and leukaemic involvement of mycosis fungoides (MF). It is associated with a more aggressive clinical course and fatal outcomes. Large cell transformation (LCT) of mycosis fungoides/Sézary syndrome is also associated with an aggressive disease course and shortened survival, requiring an intensive therapeutic approach. This report describes a case of folliculotropic Sézary syndrome with CD30+ LCT. Most of the larger lymphocytes in the lesions were positive for CD25, the expression of which is associated with advanced CTCL. In addition, we review the literature on this unusual CTCL and provide evidence that this entity represents a distinct clinicopathological entity occasionally associated with extracutaneous involvement and LCT.</p></div>
]]></content:encoded><description>

Folliculotropic Sézary syndrome is a rare and unique variant of cutaneous T-cell lymphoma (CTCL) characterised by both follicular and leukaemic involvement of mycosis fungoides (MF). It is associated with a more aggressive clinical course and fatal outcomes. Large cell transformation (LCT) of mycosis fungoides/Sézary syndrome is also associated with an aggressive disease course and shortened survival, requiring an intensive therapeutic approach. This report describes a case of folliculotropic Sézary syndrome with CD30+ LCT. Most of the larger lymphocytes in the lesions were positive for CD25, the expression of which is associated with advanced CTCL. In addition, we review the literature on this unusual CTCL and provide evidence that this entity represents a distinct clinicopathological entity occasionally associated with extracutaneous involvement and LCT.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00967.x" xmlns="http://purl.org/rss/1.0/"><title>Atypical chronic sterile paronychia leading to tissue and joint space destruction in a patient with thromboangiitis obliterans</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00967.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Atypical chronic sterile paronychia leading to tissue and joint space destruction in a patient with thromboangiitis obliterans</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Burcu Yelkovan, Keng-Ee Thai</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-06T02:10:29.155829-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00967.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00967.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00967.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We report the case of a patient with severe thromboangiitis obliterans (Buerger's disease) and untreated paronychia which eroded into the digital joint space causing acrolysis of digits and significant soft tissue and joint destruction.</p></div>
]]></content:encoded><description>

We report the case of a patient with severe thromboangiitis obliterans (Buerger's disease) and untreated paronychia which eroded into the digital joint space causing acrolysis of digits and significant soft tissue and joint destruction.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00966.x" xmlns="http://purl.org/rss/1.0/"><title>Long-term efficacy of radiofrequency ablation in treatment of common and palmo-plantar warts</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00966.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Long-term efficacy of radiofrequency ablation in treatment of common and palmo-plantar warts</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kanika Khandelwal, Ram A Bumb, Rajesh D Mehta, Bhikam C Ghiya, Abhay R Satoskar</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-06T02:10:23.699576-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00966.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00966.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00966.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Current treatments for warts induce significant local tissue damage and do not prevent recurrence. We evaluated the efficacy of localised radiofrequency heat (RFH) therapy in inducing the long-term resolution of common and palmo-plantar warts in a placebo-controlled randomised single blind trial. Our data show that RFH therapy is a safe, cosmetically acceptable and long-term effective treatment for warts.</p></div>
]]></content:encoded><description>

Current treatments for warts induce significant local tissue damage and do not prevent recurrence. We evaluated the efficacy of localised radiofrequency heat (RFH) therapy in inducing the long-term resolution of common and palmo-plantar warts in a placebo-controlled randomised single blind trial. Our data show that RFH therapy is a safe, cosmetically acceptable and long-term effective treatment for warts.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00963.x" xmlns="http://purl.org/rss/1.0/"><title>Rheumatoid neutrophilic dermatosis with tense blister formation: A case report and review of the literature</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00963.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Rheumatoid neutrophilic dermatosis with tense blister formation: A case report and review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yumi Fujio, Takeru Funakoshi, Kaori Nakayama, Masayuki Amagai, Manabu Ohyama</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-25T02:08:49.471403-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00963.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00963.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00963.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We report a 78-year-old woman with rheumatoid neutrophilic dermatosis (RND) presenting with tense blisters; an extremely rare manifestation of this condition. Systemic corticosteroid was of limited efficacy, while dapsone was effective. A literature review of four similar cases showed that tense blisters in this type of RND tended to appear on the lower extremities of aged, female rheumatoid arthritis patients. Of note, half of the cases were resistant to corticosteroids, as anti-neutrophil agents are reported to be effective. Accordingly, it is important to recognise this unusual manifestation for the timely initiation of appropriate therapy.</p></div>
]]></content:encoded><description>

We report a 78-year-old woman with rheumatoid neutrophilic dermatosis (RND) presenting with tense blisters; an extremely rare manifestation of this condition. Systemic corticosteroid was of limited efficacy, while dapsone was effective. A literature review of four similar cases showed that tense blisters in this type of RND tended to appear on the lower extremities of aged, female rheumatoid arthritis patients. Of note, half of the cases were resistant to corticosteroids, as anti-neutrophil agents are reported to be effective. Accordingly, it is important to recognise this unusual manifestation for the timely initiation of appropriate therapy.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00961.x" xmlns="http://purl.org/rss/1.0/"><title>Cutaneous mastocytosis extending beyond a radiotherapy site: A form of radiodermatitis or a neoplastic phenomenon?</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00961.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cutaneous mastocytosis extending beyond a radiotherapy site: A form of radiodermatitis or a neoplastic phenomenon?</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Samantha J Davidson, Dougal Coates</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-25T02:08:39.627531-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00961.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00961.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00961.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Ionising radiation is often used as an adjuvant in the management of breast cancer. Acute and chronic skin changes are well recognised complications associated with its use. We demonstrate a rare clinical presentation of cutaneous mastocytosis that occurred at the site of radiotherapy and then extended beyond this boundary, and ask whether this can be treated as a localised side effect of radiotherapy or whether the potential for systemic mastocytosis needs to be excluded.</p></div>
]]></content:encoded><description>

Ionising radiation is often used as an adjuvant in the management of breast cancer. Acute and chronic skin changes are well recognised complications associated with its use. We demonstrate a rare clinical presentation of cutaneous mastocytosis that occurred at the site of radiotherapy and then extended beyond this boundary, and ask whether this can be treated as a localised side effect of radiotherapy or whether the potential for systemic mastocytosis needs to be excluded.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00960.x" xmlns="http://purl.org/rss/1.0/"><title>A case of pemphigoid gestationis with concurrent IgG antibodies to BP180, BP230 and type VII collagen</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00960.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A case of pemphigoid gestationis with concurrent IgG antibodies to BP180, BP230 and type VII collagen</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Baoqi Yang, Chong Wang, Mei Wu, Donghong Du, Xiaoxiao Yan, Guizhi Zhou, Furen Zhang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-22T04:54:11.304114-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00960.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00960.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00960.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>A 22-year-old primigravida had a pruritic, erythematous, bullous eruption on the skin during the 26th week of gestation. After delivery the eruption flared up. The diagnosis of pemphigoid gestationis was confirmed based on histopathological and immunofluorescence findings. The result of immunoblotting showed IgG autoantibodies which reacted against BP230 in epidermal extracts and 290 kDa type VII collagen in dermal extracts. The BP180 antibodies were also detected by an enzyme-linked immunosorbent assay BP180NC16a diagnosis kit. Pulsed corticosteroid and cyclophosphamide resulted in a favourable response at the acute stage. The patient was cured in 2 years. The analysis of the patient's autoantibodies provides strong evidence for the involvement of epitope spreading in her autoimmune disease.</p></div>
]]></content:encoded><description>

A 22-year-old primigravida had a pruritic, erythematous, bullous eruption on the skin during the 26th week of gestation. After delivery the eruption flared up. The diagnosis of pemphigoid gestationis was confirmed based on histopathological and immunofluorescence findings. The result of immunoblotting showed IgG autoantibodies which reacted against BP230 in epidermal extracts and 290 kDa type VII collagen in dermal extracts. The BP180 antibodies were also detected by an enzyme-linked immunosorbent assay BP180NC16a diagnosis kit. Pulsed corticosteroid and cyclophosphamide resulted in a favourable response at the acute stage. The patient was cured in 2 years. The analysis of the patient's autoantibodies provides strong evidence for the involvement of epitope spreading in her autoimmune disease.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00954.x" xmlns="http://purl.org/rss/1.0/"><title>White paint dot-like lesions of the scrotum: Microsporum gypseum infection</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00954.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">White paint dot-like lesions of the scrotum: Microsporum gypseum infection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zhuo Chen, Xinling Bi, Jun Gu, Xiaoguang Xu, Ying Wang, Jianhua Wu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-09T02:46:29.102835-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00954.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00954.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00954.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>A 29-year-old renal transplant patient taking mycophenolate mofetil 1 g b.i.d., cyclosporine 100 mg b.i.d. and prednisone 10 mg q.d. presented with white paint, dot-like incrustations on the skin of his right scrotum. A 10% potassium hydroxide preparation of scrapings from the lesions showed septate hyphae and <em>Microsporum gypseum</em> was cultured. Topical bifonazole 1% cream cleared the lesions within 2 weeks. At the 2-month follow up there was no relapse.</p></div>
]]></content:encoded><description>

A 29-year-old renal transplant patient taking mycophenolate mofetil 1 g b.i.d., cyclosporine 100 mg b.i.d. and prednisone 10 mg q.d. presented with white paint, dot-like incrustations on the skin of his right scrotum. A 10% potassium hydroxide preparation of scrapings from the lesions showed septate hyphae and Microsporum gypseum was cultured. Topical bifonazole 1% cream cleared the lesions within 2 weeks. At the 2-month follow up there was no relapse.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00953.x" xmlns="http://purl.org/rss/1.0/"><title>The usefulness of dermoscopy for the recognition of basal cell carcinoma – seborrhoeic keratosis compound tumours</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00953.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The usefulness of dermoscopy for the recognition of basal cell carcinoma – seborrhoeic keratosis compound tumours</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pedro Zaballos, José Bañuls, Horacio Cabo, Álex Llambrich, Elisabeth Salsench, Susana Puig, Ángel Pizarro, Josep Malvehy</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-09T02:46:22.809927-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00953.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00953.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00953.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Dermoscopy</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00952.x" xmlns="http://purl.org/rss/1.0/"><title>A vesicular variant of pseudoverrucous papules and nodules in the genital area of an incontinent 4-year-old</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00952.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A vesicular variant of pseudoverrucous papules and nodules in the genital area of an incontinent 4-year-old</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shreya Dixit, James P Scurry, Gayle Fischer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-09T02:46:10.359911-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00952.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00952.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00952.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Irritant contact dermatitis is a common cause of chronic vulvitis in patients wearing diapers and incontinence garments. In most cases the diagnosis is obvious; however, atypical presentations may mimic more serious dermatoses. We present a 4-year-old girl who presented at birth with cloacal atresia corrected surgically and resulting in chronic incontinence requiring full-time diapers. She presented with crops of herpetiform vesicles and bullae on a base that ranged from normal skin to severe erythema and oedema. A histological examination revealed a well-demarcated lesion showing a thickened epidermis with hyperkeratosis and parakeratosis, acanthosis and an abrupt transition to pallor of the upper half. Focal full thickness epidermis necrosis and small areas of spongiosis, acantholysis and apoptotic keratinocytes were seen. Immunofluorescence was negative. The lesions improved with the treatment of secondary infection and minimal topical therapy with an emollient only. This case represents an unusual vesicular variant of pseudoverrucous papules and nodules, which has been reported only once previously.</p></div>
]]></content:encoded><description>

Irritant contact dermatitis is a common cause of chronic vulvitis in patients wearing diapers and incontinence garments. In most cases the diagnosis is obvious; however, atypical presentations may mimic more serious dermatoses. We present a 4-year-old girl who presented at birth with cloacal atresia corrected surgically and resulting in chronic incontinence requiring full-time diapers. She presented with crops of herpetiform vesicles and bullae on a base that ranged from normal skin to severe erythema and oedema. A histological examination revealed a well-demarcated lesion showing a thickened epidermis with hyperkeratosis and parakeratosis, acanthosis and an abrupt transition to pallor of the upper half. Focal full thickness epidermis necrosis and small areas of spongiosis, acantholysis and apoptotic keratinocytes were seen. Immunofluorescence was negative. The lesions improved with the treatment of secondary infection and minimal topical therapy with an emollient only. This case represents an unusual vesicular variant of pseudoverrucous papules and nodules, which has been reported only once previously.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00949.x" xmlns="http://purl.org/rss/1.0/"><title>Grover's disease secondarily infected with herpes simplex virus and Staphylococcus aureus: Case report and review</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00949.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Grover's disease secondarily infected with herpes simplex virus and Staphylococcus aureus: Case report and review</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Penelope AM Bunce, Duncan G Stanford</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-26T22:15:26.605488-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00949.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00949.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00949.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The case of a 73-year old man with <em>herpes simplex</em> and <em>staphylococcus aureus</em> infection complicating established Grover's disease is presented. This was treated successfully with valaciclovir. While reports of bacterial and herpetic infections complicating other acantholytic diseases, such as Darier's disease, have been published previously, only one publication to date shows herpes simplex infection in Grover's disease.</p></div>
]]></content:encoded><description>

The case of a 73-year old man with herpes simplex and staphylococcus aureus infection complicating established Grover's disease is presented. This was treated successfully with valaciclovir. While reports of bacterial and herpetic infections complicating other acantholytic diseases, such as Darier's disease, have been published previously, only one publication to date shows herpes simplex infection in Grover's disease.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00947.x" xmlns="http://purl.org/rss/1.0/"><title>Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00947.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marius Rademaker</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-26T22:14:58.183047-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00947.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00947.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00947.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>With 30 years of clinical use, it is appropriate to review the use of isotretinoin. We now understand that retinoids influence cellular growth, differentiation, morphogenesis and apoptosis, inhibit tumour promotion and malignant cell growth, exert immuno-modulatory actions and alter cellular cohesiveness. This has expanded the indications of isotretinoin from just acne and rosacea to a wide range of inflammatory and malignant skin disorders. While the standard dose of 0.5 to 1 mg/kg per day for 4 months to a cumulative dose of 120–140 mg/kg per day has served us well in the management of acne vulgaris, there is emerging evidence that much lower dosages (as low as 5 mg/day) are just as effective but have significantly fewer adverse effects. Relapse of acne vulgaris continues to be a problem but we are beginning to recognise that this is related less to the cumulative dose and more to the length of sebaceous gland suppression. Other factors important for relapse include a macrocomedonal pattern of acne, smoking and age, both younger (under 14 years) and older (over 25 years). After 30 years of use, we now understand why isotretinoin is such an effective drug. Not only does it clear acne in almost all patients, long-term remission can be achieved in 70–80% of patients with a single course. Important changes in the use of isotretinoin include using a lower daily dose for a longer period of time. New indications continue to emerge, particularly as a potential treatment for both intrinsic and extrinsic (photo) aging. Teratogenicity however, remains a very significant concern.</p></div>
]]></content:encoded><description>

With 30 years of clinical use, it is appropriate to review the use of isotretinoin. We now understand that retinoids influence cellular growth, differentiation, morphogenesis and apoptosis, inhibit tumour promotion and malignant cell growth, exert immuno-modulatory actions and alter cellular cohesiveness. This has expanded the indications of isotretinoin from just acne and rosacea to a wide range of inflammatory and malignant skin disorders. While the standard dose of 0.5 to 1 mg/kg per day for 4 months to a cumulative dose of 120–140 mg/kg per day has served us well in the management of acne vulgaris, there is emerging evidence that much lower dosages (as low as 5 mg/day) are just as effective but have significantly fewer adverse effects. Relapse of acne vulgaris continues to be a problem but we are beginning to recognise that this is related less to the cumulative dose and more to the length of sebaceous gland suppression. Other factors important for relapse include a macrocomedonal pattern of acne, smoking and age, both younger (under 14 years) and older (over 25 years). After 30 years of use, we now understand why isotretinoin is such an effective drug. Not only does it clear acne in almost all patients, long-term remission can be achieved in 70–80% of patients with a single course. Important changes in the use of isotretinoin include using a lower daily dose for a longer period of time. New indications continue to emerge, particularly as a potential treatment for both intrinsic and extrinsic (photo) aging. Teratogenicity however, remains a very significant concern.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00945.x" xmlns="http://purl.org/rss/1.0/"><title>Detection of novel LAMA3 mutation in Herlitz junctional epidermolysis bullosa in a Jordanian family</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00945.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Detection of novel LAMA3 mutation in Herlitz junctional epidermolysis bullosa in a Jordanian family</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eman F. Badran, Hamdi A. Battah, Kamal F Akl, Raida W. Khalil, Iyad Al Amori</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-11T05:58:45.185882-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00945.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00945.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00945.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The Herlitz junctional epidermolysis bullosa (H-JEB) subtype usually presents as a severe lethal inherited variant of epidermolysis bullosa (EB) caused by a homozygous mutation in the genes <em>LAMA3, LMAB3</em>, or <em>LAMAC3.</em> Each gene encodes one of the three chains of heterotrimer laminin-332 proteins (including the alpha-3 chain, beta-3 chain and gamma-2-chain) responsible for the adherence of the epidermis to the underlying dermis. The aim of this report is to add to the existing knowledge about EB by describing a novel mutation in a gene responsible for genodermatosis. A case of a Jordanian male neonate, born to healthy, first cousin consanguineous parents, who developed nonhealing blistering skin and mucous membrane lesions, crusted erosions with significant granulation tissue and dystrophic nails immediately after birth is described. The patient was diagnosed as having a novel <em>LAMA3</em> mutation causing (H-JEB) by immunofluorescence mapping and molecular analysis. Both parents and this baby's sibling were shown to be heterozygous carriers of the same mutation. Pre-implantation diagnosis using molecular analysis for subsequent pregnancies in this family is crucial for managing any new pregnancy.</p></div>
]]></content:encoded><description>

The Herlitz junctional epidermolysis bullosa (H-JEB) subtype usually presents as a severe lethal inherited variant of epidermolysis bullosa (EB) caused by a homozygous mutation in the genes LAMA3, LMAB3, or LAMAC3. Each gene encodes one of the three chains of heterotrimer laminin-332 proteins (including the alpha-3 chain, beta-3 chain and gamma-2-chain) responsible for the adherence of the epidermis to the underlying dermis. The aim of this report is to add to the existing knowledge about EB by describing a novel mutation in a gene responsible for genodermatosis. A case of a Jordanian male neonate, born to healthy, first cousin consanguineous parents, who developed nonhealing blistering skin and mucous membrane lesions, crusted erosions with significant granulation tissue and dystrophic nails immediately after birth is described. The patient was diagnosed as having a novel LAMA3 mutation causing (H-JEB) by immunofluorescence mapping and molecular analysis. Both parents and this baby's sibling were shown to be heterozygous carriers of the same mutation. Pre-implantation diagnosis using molecular analysis for subsequent pregnancies in this family is crucial for managing any new pregnancy.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00944.x" xmlns="http://purl.org/rss/1.0/"><title>Successful treatment of syringotropic CD8+ mycosis fungoides accompanied by hypohidrosis with vorinostat and retinoids</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00944.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Successful treatment of syringotropic CD8+ mycosis fungoides accompanied by hypohidrosis with vorinostat and retinoids</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aya Kakizaki, Taku Fujimura, Masato Mizuashi, Akiko Watabe, Yumi Kambayashi, Setsuya Aiba</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-11T05:58:19.184582-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00944.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00944.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00944.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We describe a 34-year-old Japanese man with syringotropic CD8+ mycosis fungoides (MF) accompanied by hypohidrosis who was treated with vorinostat and retinoids. Interestingly, immunohistochemical staining for dermcidin revealed a decrease of sweat in the eccrine glands, and a sweat test by the iodine starch method proved hypohidrosis in the MF-affected areas. Six months after treatment with this combination therapy, the patient's advanced MF was under control.</p></div>
]]></content:encoded><description>

We describe a 34-year-old Japanese man with syringotropic CD8+ mycosis fungoides (MF) accompanied by hypohidrosis who was treated with vorinostat and retinoids. Interestingly, immunohistochemical staining for dermcidin revealed a decrease of sweat in the eccrine glands, and a sweat test by the iodine starch method proved hypohidrosis in the MF-affected areas. Six months after treatment with this combination therapy, the patient's advanced MF was under control.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00943.x" xmlns="http://purl.org/rss/1.0/"><title>Clinical, dermoscopic and histopathological features of spontaneous scalp or face and radiotherapy-induced angiosarcoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00943.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clinical, dermoscopic and histopathological features of spontaneous scalp or face and radiotherapy-induced angiosarcoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Iris Zalaudek, Elisabeth Gomez-Moyano, Christian Landi, Miguel Lova Navarro, Maria Dolores Fernandez Ballesteros, Barbara De Pace, Angel Vera-Casaño, Simonetta Piana</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-04T03:45:32.298588-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00943.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00943.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00943.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Dermoscopy</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00942.x" xmlns="http://purl.org/rss/1.0/"><title>Trichoscopic features of various types of alopecia areata in India: application of a hand-held dermoscope</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00942.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Trichoscopic features of various types of alopecia areata in India: application of a hand-held dermoscope</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dincy Peter CV, Leni George, Susanne A. Pulimood</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-04T03:45:27.683805-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00942.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00942.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00942.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Dermoscopy</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00941.x" xmlns="http://purl.org/rss/1.0/"><title>Allergic contact stomatitis to dodecyl gallate? A review of the relevance of positive patch test results to gallates</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00941.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Allergic contact stomatitis to dodecyl gallate? A review of the relevance of positive patch test results to gallates</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sarah E Gamboni, Amanda M Palmer, Rosemary L Nixon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-04T03:45:24.178173-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00941.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00941.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00941.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Gallic acid esters or gallates are antioxidants used as preservatives in food and cosmetics. Few cases of gallates causing allergic contact dermatitis (ACD) have been reported in the literature. We present a case report of a 42-year-old beauty therapist who presented with a swollen tongue. Patch testing was positive to dodecyl gallate, commonly reported as being present in edible oil and oily foods such as margarine. Our patient avoided foods presumed to contain gallates and at the 6-week review reported a substantial improvement in her tongue symptoms. We reviewed our database and found 16 (7%) definitely or possibly relevant reactions to dodecyl gallate, seven (15%) definitely or possibly relevant reactions to propyl gallate and six (3%) definitely or possibly relevant reactions to octyl gallate. Most reactions were attributed to margarine, moisturising cream and lipstick. These products are often mentioned in the literature as containing gallates; however, ingredient labelling and discussions with manufacturers made it difficult to establish whether they are currently present in foods. Ascertaining relevance for these reactions is not always possible.</p></div>
]]></content:encoded><description>

Gallic acid esters or gallates are antioxidants used as preservatives in food and cosmetics. Few cases of gallates causing allergic contact dermatitis (ACD) have been reported in the literature. We present a case report of a 42-year-old beauty therapist who presented with a swollen tongue. Patch testing was positive to dodecyl gallate, commonly reported as being present in edible oil and oily foods such as margarine. Our patient avoided foods presumed to contain gallates and at the 6-week review reported a substantial improvement in her tongue symptoms. We reviewed our database and found 16 (7%) definitely or possibly relevant reactions to dodecyl gallate, seven (15%) definitely or possibly relevant reactions to propyl gallate and six (3%) definitely or possibly relevant reactions to octyl gallate. Most reactions were attributed to margarine, moisturising cream and lipstick. These products are often mentioned in the literature as containing gallates; however, ingredient labelling and discussions with manufacturers made it difficult to establish whether they are currently present in foods. Ascertaining relevance for these reactions is not always possible.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00940.x" xmlns="http://purl.org/rss/1.0/"><title>Improvement of palmoplantar pustulosis lesions after angioplasty for Leriche syndrome</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00940.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Improvement of palmoplantar pustulosis lesions after angioplasty for Leriche syndrome</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kazutoshi Murao, Mayumi Minato, Yoshiaki Kubo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-04T03:45:22.32142-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00940.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00940.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00940.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Although a wide range of treatments have been used in the treatment of palmoplantar pustulosis (PPP), PPP is still very difficult to treat. We report a patient who had a dramatic reduction in PPP lesions after bypass surgery for Leriche syndrome. We assume that improved blood circulation had a crucial impact in reducing PPP lesions and suggest improving blood circulation could be another treatment option.</p></div>
]]></content:encoded><description>

Although a wide range of treatments have been used in the treatment of palmoplantar pustulosis (PPP), PPP is still very difficult to treat. We report a patient who had a dramatic reduction in PPP lesions after bypass surgery for Leriche syndrome. We assume that improved blood circulation had a crucial impact in reducing PPP lesions and suggest improving blood circulation could be another treatment option.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00939.x" xmlns="http://purl.org/rss/1.0/"><title>Post-transplant plasmablastic lymphoma of the skin</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00939.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Post-transplant plasmablastic lymphoma of the skin</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Catherine L. Black, Erwin Foster-Smith, Ian D. Lewis, Randall J. Faull, Shireen K. Sidhu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-17T04:42:05.41708-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00939.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00939.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00939.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Plasmablastic lymphoma (PBL) is a recently described rare variant of diffuse large B-cell lymphoma characterised by its aggressive nature and plasmacytic differentiation. It most frequently arises in the oral cavity of human immunodeficiency virus (HIV)-infected patients. However extra-oral involvement is becoming increasingly recognised, particularly in HIV-negative patients. We report a case of PBL presenting as multiple violaceous nodules and plaques on the leg of a HIV-negative patient, 13-years post-renal transplant. To date, 20 cases of PBL presenting in the skin have been reported. We review and compare the clinico-pathological features of these cases.</p></div>
]]></content:encoded><description>

Plasmablastic lymphoma (PBL) is a recently described rare variant of diffuse large B-cell lymphoma characterised by its aggressive nature and plasmacytic differentiation. It most frequently arises in the oral cavity of human immunodeficiency virus (HIV)-infected patients. However extra-oral involvement is becoming increasingly recognised, particularly in HIV-negative patients. We report a case of PBL presenting as multiple violaceous nodules and plaques on the leg of a HIV-negative patient, 13-years post-renal transplant. To date, 20 cases of PBL presenting in the skin have been reported. We review and compare the clinico-pathological features of these cases.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00938.x" xmlns="http://purl.org/rss/1.0/"><title>Recurrent menstrual toxic shock syndrome despite discontinuation of tampon use: Is menstrual toxic shock syndrome really caused by tampons?</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00938.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Recurrent menstrual toxic shock syndrome despite discontinuation of tampon use: Is menstrual toxic shock syndrome really caused by tampons?</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shreya Dixit, Gayle Fischer, Carola Wittekind</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-17T04:40:42.198472-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00938.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00938.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00938.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Menstrual toxic shock syndrome (MTSS) is a rare and potentially life-threatening illness. We present a case of recurrent MTSS initially associated with tampon use that continued to recur when tampons were discontinued, which was successfully treated with rifampicin and clindamycin.</p></div>
]]></content:encoded><description>

Menstrual toxic shock syndrome (MTSS) is a rare and potentially life-threatening illness. We present a case of recurrent MTSS initially associated with tampon use that continued to recur when tampons were discontinued, which was successfully treated with rifampicin and clindamycin.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00923.x" xmlns="http://purl.org/rss/1.0/"><title>Intralymphatic granulomas in lymphoedema secondary to anogenital granulomatosis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00923.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Intralymphatic granulomas in lymphoedema secondary to anogenital granulomatosis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amanda Saracino, Kristiana Gordon, Lorette Ffolkes, Peter S Mortimer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-11T05:06:41.329357-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00923.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00923.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00923.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The granulomatous inflammation seen in filariasis, orofacial granulomatosis (OFG), rosacea and sarcoidosis can be associated with lymphoedema. In the setting of OFG, the finding of intralymphatic granulomas has been reported as a possible mechanism for lymphoedema. Anogenital granulomatosis (AGG) is a similar chronic inflammatory condition of unknown pathogenesis. It presents as granulomatous genital or anoperineal inflammation and associated lymphoedema, with histological findings of non-caseating granulomas and a perivascular infiltrate. We report a case of AGG and lymphoedema with intralymphatic granulomas seen on biopsy. This finding is unique and we propose that the intralymphatic granulomatous inflammation causes a partial or complete occlusion of lymphatic drainage, thus resulting in the clinical situation of lymphoedema.</p></div>]]></content:encoded><description>The granulomatous inflammation seen in filariasis, orofacial granulomatosis (OFG), rosacea and sarcoidosis can be associated with lymphoedema. In the setting of OFG, the finding of intralymphatic granulomas has been reported as a possible mechanism for lymphoedema. Anogenital granulomatosis (AGG) is a similar chronic inflammatory condition of unknown pathogenesis. It presents as granulomatous genital or anoperineal inflammation and associated lymphoedema, with histological findings of non-caseating granulomas and a perivascular infiltrate. We report a case of AGG and lymphoedema with intralymphatic granulomas seen on biopsy. This finding is unique and we propose that the intralymphatic granulomatous inflammation causes a partial or complete occlusion of lymphatic drainage, thus resulting in the clinical situation of lymphoedema.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00921.x" xmlns="http://purl.org/rss/1.0/"><title>Paraneoplastic pemphigus</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00921.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Paraneoplastic pemphigus</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Angeline Anning Yong, Hong Liang Tey</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-03T04:02:56.888383-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00921.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00921.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00921.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Paraneoplastic pemphigus (PNP) is a distinct autoimmune blistering disease that can affect multiple organs other than the skin. It occurs in association with certain neoplasms, among which lymphoproliferative diseases are most commonly associated. The clinical presentation of PNP consists typically of painful, severe oral erosions that may be accompanied by a generalised cutaneous eruption and systemic involvement. The eruption may be of different morphology, consisting of lesions that resemble pemphigus, pemphigoid, erythema multiforme or graft versus host disease, as well as lesions resembling lichen planus. Similarly, the histological findings also show considerable variability. PNP is characterised by the presence of autoantibodies against various antigens: desmoplakin I (250 kd), bullous pemphigoid antigen I (230 kd), desmoplakin II (210 kd), envoplakin (210 kd), periplakin (190 kd), plectin (500 kd) and a 170-kd protein. This 170-kd protein has recently been identified as alpha-2-macroglobulin-like-1, a broad range protease inhibitor expressed in stratified epithelia and other tissue damaged in PNP. The prognosis of PNP is poor and the disease is often fatal. Immunosuppressive agents are often required to decrease blistering, and treating the underlying malignancy with chemotherapy may control autoantibody production. The prognosis is better when PNP is associated with benign tumours and these should be surgically excised when possible.</p></div>]]></content:encoded><description>Paraneoplastic pemphigus (PNP) is a distinct autoimmune blistering disease that can affect multiple organs other than the skin. It occurs in association with certain neoplasms, among which lymphoproliferative diseases are most commonly associated. The clinical presentation of PNP consists typically of painful, severe oral erosions that may be accompanied by a generalised cutaneous eruption and systemic involvement. The eruption may be of different morphology, consisting of lesions that resemble pemphigus, pemphigoid, erythema multiforme or graft versus host disease, as well as lesions resembling lichen planus. Similarly, the histological findings also show considerable variability. PNP is characterised by the presence of autoantibodies against various antigens: desmoplakin I (250 kd), bullous pemphigoid antigen I (230 kd), desmoplakin II (210 kd), envoplakin (210 kd), periplakin (190 kd), plectin (500 kd) and a 170-kd protein. This 170-kd protein has recently been identified as alpha-2-macroglobulin-like-1, a broad range protease inhibitor expressed in stratified epithelia and other tissue damaged in PNP. The prognosis of PNP is poor and the disease is often fatal. Immunosuppressive agents are often required to decrease blistering, and treating the underlying malignancy with chemotherapy may control autoantibody production. The prognosis is better when PNP is associated with benign tumours and these should be surgically excised when possible.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00919.x" xmlns="http://purl.org/rss/1.0/"><title>A puzzling case: SCC or not?</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00919.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A puzzling case: SCC or not?</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susan Simpkin, Duncan Lamont, Anthony Yung</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-03T04:00:55.922903-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00919.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00919.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00919.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Brief Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We present a 37-year-old woman who underwent extensive facial surgery for removal of multiple eruptive squamous cell carcinoma (SCC)-like lesions resembling invasive SCC histologically. The patient's mother had undergone numerous surgical procedures and radiotherapy for facial SCC. A review of the histology and immunohistochemistry for DNA mismatch repair proteins excluded Muir–Torre syndrome. A diagnosis of Ferguson-Smith disease (or multiple self-healing squamous epitheliomata) was suspected. Blood was sent for DNA analysis. Twelve months later, mutations of the TGFBR1 gene were demonstrated in 18 families (67 individuals) with Ferguson-Smith disease; among whom our patient and her mother were family 11.</p></div>]]></content:encoded><description>We present a 37-year-old woman who underwent extensive facial surgery for removal of multiple eruptive squamous cell carcinoma (SCC)-like lesions resembling invasive SCC histologically. The patient's mother had undergone numerous surgical procedures and radiotherapy for facial SCC. A review of the histology and immunohistochemistry for DNA mismatch repair proteins excluded Muir–Torre syndrome. A diagnosis of Ferguson-Smith disease (or multiple self-healing squamous epitheliomata) was suspected. Blood was sent for DNA analysis. Twelve months later, mutations of the TGFBR1 gene were demonstrated in 18 families (67 individuals) with Ferguson-Smith disease; among whom our patient and her mother were family 11.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00907.x" xmlns="http://purl.org/rss/1.0/"><title>Localised giant haematoma and subsequent widespread purpura as a sign of acquired haemophilia A</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00907.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Localised giant haematoma and subsequent widespread purpura as a sign of acquired haemophilia A</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Naoki Oiso, Chikara Hirase, Yasuyoshi Morita, Ayaka Hirao, Shusuke Uchida, Atsushi Sasakawa, Mami Toyomasu, Yoichi Tatsumi, Itaru Matsumura, Akira Kawada</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-06-12T04:25:35.442903-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00907.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00907.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00907.x</prism:url><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">no</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">no</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Patients with acquired haemophilia A usually show widespread subcutaneous bleeding. We describe an 86-year-old man with acquired haemophilia A associated with prostate carcinoma, showing initial localised giant haematoma and subsequent widespread subcutaneous bleeding. A localised giant haematoma may present as a first and important sign of acquired haemophilia A.</p></div>]]></content:encoded><description>Patients with acquired haemophilia A usually show widespread subcutaneous bleeding. We describe an 86-year-old man with acquired haemophilia A associated with prostate carcinoma, showing initial localised giant haematoma and subsequent widespread subcutaneous bleeding. A localised giant haematoma may present as a first and important sign of acquired haemophilia A.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00904.x" xmlns="http://purl.org/rss/1.0/"><title>Pulmonary metastases: A rare manifestation of the most common cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00904.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pulmonary metastases: A rare manifestation of the most common cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Surein Arulananda, Mun Sem Liew, Shane Battye, Christine F McDonald, Paul Mitchell</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-06-06T06:15:40.575563-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00904.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00904.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00904.x</prism:url><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">no</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">no</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Basal cell carcinoma (BCC) is the most common human malignancy but rarely metastasises. We report on two patients with symptomatic lung metastases and a past history of recurrent BCC excisions. In our first patient, a heavy smoker with multiple lung lesions, histology of a resected nodule was first reported as non-small cell lung cancer but a repeat nodule biopsy a year later was recognised as a pulmonary metastasis from primary cutaneous BCC. Our second patient, a young never-smoker with two previous BCC, was confirmed as having a pulmonary metastasis from BCC on the lung resection specimen. Pulmonary metastasis from an unidentified primary site is a common clinical situation. These patients emphasise the importance of considering the most common cancer as a potential primary.</p></div>]]></content:encoded><description>Basal cell carcinoma (BCC) is the most common human malignancy but rarely metastasises. We report on two patients with symptomatic lung metastases and a past history of recurrent BCC excisions. In our first patient, a heavy smoker with multiple lung lesions, histology of a resected nodule was first reported as non-small cell lung cancer but a repeat nodule biopsy a year later was recognised as a pulmonary metastasis from primary cutaneous BCC. Our second patient, a young never-smoker with two previous BCC, was confirmed as having a pulmonary metastasis from BCC on the lung resection specimen. Pulmonary metastasis from an unidentified primary site is a common clinical situation. These patients emphasise the importance of considering the most common cancer as a potential primary.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00896.x" xmlns="http://purl.org/rss/1.0/"><title>A curious serendipitous finding: Spitz naevus combined with a syringoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00896.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A curious serendipitous finding: Spitz naevus combined with a syringoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Simonetta Piana, Moira Ragazzi, Iris Zalaudek, Giuseppe Argenziano</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-06-04T04:55:25.826579-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00896.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00896.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00896.x</prism:url><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">no</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">no</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Combined tumours are often a serendipitous finding. Among the spectrum of melanocytic tumours, the co-existence of different cell populations of the same linage is a well-recognised phenomenon. Less commonly documented, but still well documented is the event of a melanocytic tumour in collision with an epithelial benign or malignant neoplasm. Exceptionally infrequent is however the collision of a Spitz naevus with an epithelial tumour. Here we report the clinical-dermoscopic and histopathological findings of a Spitz naevus occurring in collision with a syringoma.</p></div>]]></content:encoded><description>Combined tumours are often a serendipitous finding. Among the spectrum of melanocytic tumours, the co-existence of different cell populations of the same linage is a well-recognised phenomenon. Less commonly documented, but still well documented is the event of a melanocytic tumour in collision with an epithelial benign or malignant neoplasm. Exceptionally infrequent is however the collision of a Spitz naevus with an epithelial tumour. Here we report the clinical-dermoscopic and histopathological findings of a Spitz naevus occurring in collision with a syringoma.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00886.x" xmlns="http://purl.org/rss/1.0/"><title>Multifocal skin basal cell carcinomata 57 years after topical dry ice treatment</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00886.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Multifocal skin basal cell carcinomata 57 years after topical dry ice treatment</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julan V Amalaseelan, Lionel J Lukin, Michael J McKay</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-03-27T12:41:35.623024-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00886.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00886.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00886.x</prism:url><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">no</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">no</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We report a rare case of simultaneous multiple basal cell carcinomata occurring on the back of a patient who had received dry ice treatment to this area almost 6 decades previously. This is also one of the longest recorded disease-free intervals between skin trauma and basal cell carcinoma development. We discuss the aetiopathology of multiple skin cancers in our patient and the propensity for destructive skin events to predispose to malignancy.</p></div>]]></content:encoded><description>We report a rare case of simultaneous multiple basal cell carcinomata occurring on the back of a patient who had received dry ice treatment to this area almost 6 decades previously. This is also one of the longest recorded disease-free intervals between skin trauma and basal cell carcinoma development. We discuss the aetiopathology of multiple skin cancers in our patient and the propensity for destructive skin events to predispose to malignancy.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00873.x" xmlns="http://purl.org/rss/1.0/"><title>A case of hypocomplementaemic urticarial vasculitis with a high serum level of rheumatoid factor</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00873.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A case of hypocomplementaemic urticarial vasculitis with a high serum level of rheumatoid factor</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Atsuko Ashida, Hiroshi Murata, Atsuko Ohashi, Eisaku Ogawa, Hisashi Uhara, Ryuhei Okuyama</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-23T13:26:47.055306-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00873.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00873.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00873.x</prism:url><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">no</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">no</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We report a case of hypocomplementaemic urticarial vasculitis with an elevated serum rheumatoid factor level. Hypocomplementaemic urticarial vasculitis is an immune complex-mediated disease characterised by urticarial eruptions. High levels of rheumatoid factor may be associated with hypocomplementaemia due to the consumption of complement, because the rheumatoid factor can form immune complexes with immunoglobulin. It is necessary to pay attention to the amounts of complement in cases of urticarial eruptions with elevated rheumatoid factor level. The eruptions were relieved with a combination of prednisolone and colchicine.</p></div>]]></content:encoded><description>We report a case of hypocomplementaemic urticarial vasculitis with an elevated serum rheumatoid factor level. Hypocomplementaemic urticarial vasculitis is an immune complex-mediated disease characterised by urticarial eruptions. High levels of rheumatoid factor may be associated with hypocomplementaemia due to the consumption of complement, because the rheumatoid factor can form immune complexes with immunoglobulin. It is necessary to pay attention to the amounts of complement in cases of urticarial eruptions with elevated rheumatoid factor level. The eruptions were relieved with a combination of prednisolone and colchicine.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00911.x" xmlns="http://purl.org/rss/1.0/"><title>Food allergy testing in infantile eczema: A clinical approach and algorithm</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00911.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Food allergy testing in infantile eczema: A clinical approach and algorithm</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kate Newland, Lachlan Warren, Michael Gold</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-06-12T04:28:37.737365-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00911.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00911.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00911.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">REVIEW ARTICLE</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">79</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">84</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The complex relationship between food allergy and infantile eczema has prompted divergent approaches to investigating potential food triggers in eczematous patients. It is well recognised that a significant proportion of infants with eczema have immunoglobulin E-mediated food allergy, reported to range between 20–80%. Determining whether certain foods trigger an eczematous flare in individual infants with eczema is difficult. For all infants with eczema, good skin care is the mainstay of treatment but identifying and avoiding triggers (both allergic and non-allergic) is important in some infants. Given this, we have a developed an algorithm that can be used by dermatologists in the investigation and management of food allergies in infantile eczema. Issues such as patient selection, investigation and elimination diets are addressed, with reference to relevant evidence in the literature. Our aim is to provide dermatologists with a framework to manage food allergies in infantile eczema, allowing the problem to be addressed with confidence.</p></div>
]]></content:encoded><description>

The complex relationship between food allergy and infantile eczema has prompted divergent approaches to investigating potential food triggers in eczematous patients. It is well recognised that a significant proportion of infants with eczema have immunoglobulin E-mediated food allergy, reported to range between 20–80%. Determining whether certain foods trigger an eczematous flare in individual infants with eczema is difficult. For all infants with eczema, good skin care is the mainstay of treatment but identifying and avoiding triggers (both allergic and non-allergic) is important in some infants. Given this, we have a developed an algorithm that can be used by dermatologists in the investigation and management of food allergies in infantile eczema. Issues such as patient selection, investigation and elimination diets are addressed, with reference to relevant evidence in the literature. Our aim is to provide dermatologists with a framework to manage food allergies in infantile eczema, allowing the problem to be addressed with confidence.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00950.x" xmlns="http://purl.org/rss/1.0/"><title>Infant feeding and the development of food allergies and atopic eczema: An update</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00950.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Infant feeding and the development of food allergies and atopic eczema: An update</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sarah E Gamboni, Katrina J Allen, Rosemary L Nixon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-22T04:53:53.055772-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00950.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00950.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00950.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">REVIEW ARTICLE</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">85</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">89</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>There is an increasing awareness of food allergies in the community. Dermatologists frequently see patients with atopic eczema, where parents are extremely concerned about the role of food allergy. Advice given to parents regarding the timing of introduction of solid foods has changed markedly over the past decade. Whereas previous advice advocated delaying the introduction of solid foods until the infant's gastrointestinal system had matured, recent studies suggest that the introduction of solids from around 4 to 6 months may actually prevent the development of allergies. Studies on maternal dietary restrictions during pregnancy and lactation have led researchers to believe that antigen avoidance does not play a significant role in the prevention of atopic disease. Breastfeeding exclusively for 4 to 6 months has multiple benefits for mother and child, however, it does not convincingly prevent food allergies or decrease atopic eczema. New evidence suggests that the use of hydrolysed formulas does not delay or prevent atopic eczema or food allergy. This article aims to highlight current evidence and provide an update for dermatologists on the role of food exposure in the development of atopic disease, namely atopic eczema.</p></div>
]]></content:encoded><description>

There is an increasing awareness of food allergies in the community. Dermatologists frequently see patients with atopic eczema, where parents are extremely concerned about the role of food allergy. Advice given to parents regarding the timing of introduction of solid foods has changed markedly over the past decade. Whereas previous advice advocated delaying the introduction of solid foods until the infant's gastrointestinal system had matured, recent studies suggest that the introduction of solids from around 4 to 6 months may actually prevent the development of allergies. Studies on maternal dietary restrictions during pregnancy and lactation have led researchers to believe that antigen avoidance does not play a significant role in the prevention of atopic disease. Breastfeeding exclusively for 4 to 6 months has multiple benefits for mother and child, however, it does not convincingly prevent food allergies or decrease atopic eczema. New evidence suggests that the use of hydrolysed formulas does not delay or prevent atopic eczema or food allergy. This article aims to highlight current evidence and provide an update for dermatologists on the role of food exposure in the development of atopic disease, namely atopic eczema.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00968.x" xmlns="http://purl.org/rss/1.0/"><title>Associations between aberrant DNA methylation and transcript levels of DNMT1 and MBD2 in CD4+T cells from patients with systemic lupus erythematosus</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00968.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Associations between aberrant DNA methylation and transcript levels of DNMT1 and MBD2 in CD4+T cells from patients with systemic lupus erythematosus</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hai-Hong Qin, Xiao-Hua Zhu, Jun Liang, Yong-Sheng Yang, Shang-Shang Wang, Wei-Min Shi, Jin-Hua Xu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-06T02:10:34.885708-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00968.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00968.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00968.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">ORIGINAL RESEARCH</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">90</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">95</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="ajd968-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background/Objectives</h4><div class="para"><p>It seems that global DNA hypomethylation in CD4+T cells is linked to the pathogenesis of systemic lupus erythematosus (SLE). However, the underlying mechanism by which SLE patients show hypomethylated DNA remains unclear. This study explored the relationship between DNA methylation patterns and expression levels of DNA methyltransferases (DNMT1) and MBD2 in CD4+T cells of SLE patients.</p></div></div>
<div class="section" id="ajd968-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>CD4+T cells were obtained from 30 patients with SLE and 18 normal controls. The global DNA methylation levels in CD4+T cells were evaluated by the Methyflash DNA methylation quantification kit. The mRNA levels of DNMT1 and MBD2 were quantified by quantitative real-time polymerase chain reaction.</p></div></div>
<div class="section" id="ajd968-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>SLE patients had significantly lower global DNA methylation levels than controls, and the global DNA methylation was inversely correlated with the SLE disease activity index (SLEDAI). The mRNA levels of DNMT1 in SLE patients were significantly lower than that of controls and there was no correlation between DNMT1 mRNA levels and SLEDAI but there was a positive correlation between DNMT1 mRNA levels and global DNA methylation. The mRNA levels of MBD2 in SLE patients were significantly higher than in controls, and there was positive correlation between MBD2 mRNA levels and SLEDAI and an inverse correlation between MBD2 mRNA levels and global DNA methylation.</p></div></div>
<div class="section" id="ajd968-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Global DNA hypomethylation may play a pivotal role in the pathogenesis of SLE. Abnormal expression levels of DNMT1 and MBD2 mRNA may be important causes of the global hypomethylation observed in CD4+T cells in SLE.</p></div></div>
]]></content:encoded><description>


Background/Objectives
It seems that global DNA hypomethylation in CD4+T cells is linked to the pathogenesis of systemic lupus erythematosus (SLE). However, the underlying mechanism by which SLE patients show hypomethylated DNA remains unclear. This study explored the relationship between DNA methylation patterns and expression levels of DNA methyltransferases (DNMT1) and MBD2 in CD4+T cells of SLE patients.


Methods
CD4+T cells were obtained from 30 patients with SLE and 18 normal controls. The global DNA methylation levels in CD4+T cells were evaluated by the Methyflash DNA methylation quantification kit. The mRNA levels of DNMT1 and MBD2 were quantified by quantitative real-time polymerase chain reaction.


Results
SLE patients had significantly lower global DNA methylation levels than controls, and the global DNA methylation was inversely correlated with the SLE disease activity index (SLEDAI). The mRNA levels of DNMT1 in SLE patients were significantly lower than that of controls and there was no correlation between DNMT1 mRNA levels and SLEDAI but there was a positive correlation between DNMT1 mRNA levels and global DNA methylation. The mRNA levels of MBD2 in SLE patients were significantly higher than in controls, and there was positive correlation between MBD2 mRNA levels and SLEDAI and an inverse correlation between MBD2 mRNA levels and global DNA methylation.


Conclusions
Global DNA hypomethylation may play a pivotal role in the pathogenesis of SLE. Abnormal expression levels of DNMT1 and MBD2 mRNA may be important causes of the global hypomethylation observed in CD4+T cells in SLE.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12001" xmlns="http://purl.org/rss/1.0/"><title>Influence of time on dermoscopic diagnosis and management</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12001</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Influence of time on dermoscopic diagnosis and management</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Natalia Jaimes, Stephen W. Dusza, Elizabeth A. Quigley, Ralph P. Braun, Susana Puig, Josep Malvehy, Harald Kittler, Harold S. Rabinovitz, Margaret C. Oliviero, H. Peter Soyer, James M. Grichnik, Adam Korzenko, Horacio Cabo, Blanca Carlos-Ortega, Verena Ahlgrimm-Siess, Alfred W. Kopf, Ashfaq A. Marghoob</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-29T03:50:20.653238-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12001</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12001</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12001</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">ORIGINAL RESEARCH</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">96</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">104</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="ajd12001-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background/Objectives</h4><div class="para"><p>Dermoscopy aids in clinical decision-making. However, time pressure is a common reason precluding its use. We evaluated the effect of time on lesion recognition and management decisions utilising clinical and dermoscopic images.</p></div></div>
<div class="section" id="ajd12001-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Method</h4><div class="para"><p>In all, 100 dermoscopic images were presented to 15 dermatologists with experience in dermoscopy and seven non-experts (dermatology residents). Each lesion was displayed thrice in succession. The dermoscopic image was initially presented for 1 s (t1). The same dermoscopic image was shown again without time constraints (t2) and then a final time with additional images of the clinical context (t3). Participants provided a diagnosis, their level of confidence and biopsy predilection after evaluating each image.</p></div></div>
<div class="section" id="ajd12001-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>For benign lesions, both groups rarely changed their diagnosis. However, an improvement in the number of correct benign diagnoses was observed when the lesion was shown in a clinical context. For malignant lesions, both groups improved when more time and clinical context was given; nevertheless, non-experts were more likely to change the diagnosis towards the correct one as more time was given and tended to perform more biopsies, in particular of benign lesions. Limitations were a small number of participants and an artificial study setting.</p></div></div>
<div class="section" id="ajd12001-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Dermoscopy uses analytical and non-analytical reasoning approaches. We suggest that non-analytical reasoning is employed when rapid clinical decisions need to be made, especially during the evaluation of benign lesions. We conclude that dermoscopy is relatively rapid and non–time-consuming technique that adds relevant information and guides clinicians towards appropriate management decisions.</p></div></div>
]]></content:encoded><description>


Background/Objectives
Dermoscopy aids in clinical decision-making. However, time pressure is a common reason precluding its use. We evaluated the effect of time on lesion recognition and management decisions utilising clinical and dermoscopic images.


Method
In all, 100 dermoscopic images were presented to 15 dermatologists with experience in dermoscopy and seven non-experts (dermatology residents). Each lesion was displayed thrice in succession. The dermoscopic image was initially presented for 1 s (t1). The same dermoscopic image was shown again without time constraints (t2) and then a final time with additional images of the clinical context (t3). Participants provided a diagnosis, their level of confidence and biopsy predilection after evaluating each image.


Results
For benign lesions, both groups rarely changed their diagnosis. However, an improvement in the number of correct benign diagnoses was observed when the lesion was shown in a clinical context. For malignant lesions, both groups improved when more time and clinical context was given; nevertheless, non-experts were more likely to change the diagnosis towards the correct one as more time was given and tended to perform more biopsies, in particular of benign lesions. Limitations were a small number of participants and an artificial study setting.


Conclusion
Dermoscopy uses analytical and non-analytical reasoning approaches. We suggest that non-analytical reasoning is employed when rapid clinical decisions need to be made, especially during the evaluation of benign lesions. We conclude that dermoscopy is relatively rapid and non–time-consuming technique that adds relevant information and guides clinicians towards appropriate management decisions.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12027" xmlns="http://purl.org/rss/1.0/"><title>Complementary role of a polymerase chain reaction test in the diagnosis of onychomycosis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12027</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Complementary role of a polymerase chain reaction test in the diagnosis of onychomycosis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nisha Suyien Chandran, Jiun-Yit Pan, Zacharias AD Pramono, Hiok-Hee Tan, Chew-Swee Seow</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T00:49:48.325281-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12027</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12027</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12027</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">ORIGINAL RESEARCH</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">105</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">108</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="ajd12027-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The successful treatment of onychomycosis depends on accurate diagnosis. Conventional diagnostic methods, including direct microscopy and fungal culture, are non-specific, insensitive and time-consuming. Recently, PCR has shown promise in improving the diagnosis of onychomycosis. We aimed to evaluate a commercially available PCR kit for the <em>in vitro</em> detection of dermatophytes and specifically <em>Trichophyton rubrum</em> in nail specimens with suspected onychomycosis, and to compare the detection rates of PCR with conventional diagnostic methods.</p></div></div>
<div class="section" id="ajd12027-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Nail specimens were prospectively collected from patients with clinically suspected onychomycosis. All nail specimens were positive on direct microscopic examination. PCR and fungal cultures were administered, and the detection rates of dermatophytes were compared.</p></div></div>
<div class="section" id="ajd12027-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p> In all, 107 nail specimens were analysed. The fungal culture was positive in 57 (53%) specimens (38 dermatophytes and 19 non-dermatophytes). PCR was positive in 77 (72%) specimens (63 <em>T. rubrum</em> and 14 pan-dermatophyte). A total of 37 specimens (35%) were positive for both fungal culture and PCR. PCR detected dermatophytes in 39 specimens that were missed by the fungal culture, increasing the diagnosis of dermatophyte-positive specimens by 37%. Five dermatophyte–culture-positive specimens were negative for PCR.</p></div></div>
<div class="section" id="ajd12027-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>This study demonstrates that PCR increases the sensitivity of detection of dermatophytes in nail specimens. Despite its limitations, the use of PCR can complement direct microscopic examination and fungal cultures to aid clinicians in the diagnosis of suspected dermatophytic onychomycosis.</p></div></div>
]]></content:encoded><description>


Background
The successful treatment of onychomycosis depends on accurate diagnosis. Conventional diagnostic methods, including direct microscopy and fungal culture, are non-specific, insensitive and time-consuming. Recently, PCR has shown promise in improving the diagnosis of onychomycosis. We aimed to evaluate a commercially available PCR kit for the in vitro detection of dermatophytes and specifically Trichophyton rubrum in nail specimens with suspected onychomycosis, and to compare the detection rates of PCR with conventional diagnostic methods.


Methods
Nail specimens were prospectively collected from patients with clinically suspected onychomycosis. All nail specimens were positive on direct microscopic examination. PCR and fungal cultures were administered, and the detection rates of dermatophytes were compared.


Results
 In all, 107 nail specimens were analysed. The fungal culture was positive in 57 (53%) specimens (38 dermatophytes and 19 non-dermatophytes). PCR was positive in 77 (72%) specimens (63 T. rubrum and 14 pan-dermatophyte). A total of 37 specimens (35%) were positive for both fungal culture and PCR. PCR detected dermatophytes in 39 specimens that were missed by the fungal culture, increasing the diagnosis of dermatophyte-positive specimens by 37%. Five dermatophyte–culture-positive specimens were negative for PCR.

 Conclusions
This study demonstrates that PCR increases the sensitivity of detection of dermatophytes in nail specimens. Despite its limitations, the use of PCR can complement direct microscopic examination and fungal cultures to aid clinicians in the diagnosis of suspected dermatophytic onychomycosis.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12028" xmlns="http://purl.org/rss/1.0/"><title>Nasal carriage of Staphylococcus aureus in patients undergoing Mohs micrographic surgery is an important risk factor for postoperative surgical site infection: A prospective randomised study</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12028</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Nasal carriage of Staphylococcus aureus in patients undergoing Mohs micrographic surgery is an important risk factor for postoperative surgical site infection: A prospective randomised study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yee J Tai, Kate LA Borchard, Todd H Gunson, Harvey R Smith, Carl Vinciullo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T00:49:50.889426-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12028</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12028</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12028</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">ORIGINAL RESEARCH</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">109</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">114</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="ajd12028-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Surgical site infection (SSI) can be a problematic complication of Mohs micrographic surgery (MMS). Previous reports have cited nasal <em>Staphylococcus aureus</em> (<em>S. aureus</em>) carriage as a risk factor for SSI, but none thus far in dermatologic surgery.</p></div></div>
<div class="section" id="ajd12028-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Objective</h4><div class="para"><p>The aim was to determine the difference in infection rates between nasal carriers of <em>S. aureus</em> and non-carriers, and whether decolonisation with intranasal mupirocin ointment and chlorhexidine wash would reduce the infection rate in nasal carriers.</p></div></div>
<div class="section" id="ajd12028-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In all, 738 patients presenting for MMS at the Oxford Day Surgery and Dermatology underwent a nasal swab to determine their <em>S. aureus</em> carriage status. <em>S. aureus</em> carriers were randomised for decolonisation with intranasal mupirocin ointment and chlorhexidine body wash. Non-carriers were untreated. All patients were followed up for SSI.</p></div></div>
<div class="section" id="ajd12028-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The rate of SSI was 11 per cent in untreated <em>S. aureus</em> carriers, 4 per cent in treated carriers, and 3 per cent in non-carriers. The difference in infection rate between carriers and non-carriers was significant (<em>P</em> &lt; 0.001). The difference between treated and untreated carriers was also significant (<em>P</em> = 0.05).</p></div></div>
<div class="section" id="ajd12028-sec-0005" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Nasal <em>S. aureus</em> carriage is an important risk factor for SSI in MMS, conferring an over threefold increase in SSI risk. A pre-operative nasal swab provides a simple and effective risk stratification tool. The use of a topical decolonisation regimen reduces the infection rate in carriers to a level approaching non-carriers without exposure to systemic antibiotics.</p></div></div>
]]></content:encoded><description>


Background
Surgical site infection (SSI) can be a problematic complication of Mohs micrographic surgery (MMS). Previous reports have cited nasal Staphylococcus aureus (S. aureus) carriage as a risk factor for SSI, but none thus far in dermatologic surgery.


Objective
The aim was to determine the difference in infection rates between nasal carriers of S. aureus and non-carriers, and whether decolonisation with intranasal mupirocin ointment and chlorhexidine wash would reduce the infection rate in nasal carriers.


Methods
In all, 738 patients presenting for MMS at the Oxford Day Surgery and Dermatology underwent a nasal swab to determine their S. aureus carriage status. S. aureus carriers were randomised for decolonisation with intranasal mupirocin ointment and chlorhexidine body wash. Non-carriers were untreated. All patients were followed up for SSI.


Results
The rate of SSI was 11 per cent in untreated S. aureus carriers, 4 per cent in treated carriers, and 3 per cent in non-carriers. The difference in infection rate between carriers and non-carriers was significant (P &lt; 0.001). The difference between treated and untreated carriers was also significant (P = 0.05).


Conclusion
Nasal S. aureus carriage is an important risk factor for SSI in MMS, conferring an over threefold increase in SSI risk. A pre-operative nasal swab provides a simple and effective risk stratification tool. The use of a topical decolonisation regimen reduces the infection rate in carriers to a level approaching non-carriers without exposure to systemic antibiotics.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12029" xmlns="http://purl.org/rss/1.0/"><title>Dexamethasone iontophoresis for the treatment of nail psoriasis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12029</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Dexamethasone iontophoresis for the treatment of nail psoriasis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Quynh Van Le, Anne Howard</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T00:49:53.908422-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12029</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12029</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12029</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">ORIGINAL RESEARCH</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">115</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">119</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="ajd12029-sec-1001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Severe nail psoriasis can impact significantly on quality of life and is difficult to treat.</p></div></div>
<div class="section" id="ajd12029-sec-1002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>This is a retrospective study of all patients treated with dexamethasone iontophoresis weekly for at least 3 months at our specialist nail clinic between 1996 and 2011. Response to treatment was assessed on clinical photographs using the nail psoriasis severity index (NAPSI) scoring.</p></div></div>
<div class="section" id="ajd12029-sec-1003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In all, 27 patients were assessed, of whom 81 per cent showed an improvement in their nails. The treatment was well tolerated, with only one patient reporting fissuring of the fingertips.</p></div></div>
<div class="section" id="ajd12029-sec-1004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Dexamethasone iontophoresis may be a useful treatment of this generally recalcitrant condition.</p></div></div>
]]></content:encoded><description>


Background
Severe nail psoriasis can impact significantly on quality of life and is difficult to treat.


Methods
This is a retrospective study of all patients treated with dexamethasone iontophoresis weekly for at least 3 months at our specialist nail clinic between 1996 and 2011. Response to treatment was assessed on clinical photographs using the nail psoriasis severity index (NAPSI) scoring.


Results
In all, 27 patients were assessed, of whom 81 per cent showed an improvement in their nails. The treatment was well tolerated, with only one patient reporting fissuring of the fingertips.


Conclusions
Dexamethasone iontophoresis may be a useful treatment of this generally recalcitrant condition.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00962.x" xmlns="http://purl.org/rss/1.0/"><title>The protective effects of 6-CySeCD with GPx activity against UVB-induced injury in HaCaT cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00962.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The protective effects of 6-CySeCD with GPx activity against UVB-induced injury in HaCaT cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xin Li, Lin Zhang, Ya-Wei Xu, Cheng Wang, Yang Zhao, Ping Yu, Shao-Wu Lv, Gang-Lin Yan, Jun-Qiu Liu, Gui-Min Luo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-25T02:08:44.645212-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00962.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00962.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00962.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">ORIGINAL RESEARCH</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">120</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">125</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="ajd962-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The generation of harmful reactive oxygen species (ROS) induced by UVB irradiation could induce cell apoptosis and change the cell cycle. 6A,6A′-dicyclohexylamine-6B,6B′-diselenide-bis-β-cyclodextrin (6-CySeCD) is a novel glutathione peroxidase (GPx; EC 1.11.1.9) mimic. The aim of this study was to investigate the anti-oxidative effects of 6-CySeCD in cultured immortalised human keratinocyte cells (HaCaT).</p></div></div>
<div class="section" id="ajd962-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>HaCaT cells were treated with 30 mJ/cm<sup>2</sup> UVB to establish a damage model. The cultured HaCaT cells were randomly assigned to the control, UVB and treatment groups. The treatment group was incubated with 20 μmol/L of GPx mimics before UVB irradiation. Cell viability was detected by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, the level of lipid peroxidation was determined by the formation of malondialdehyde (MDA), DNA fragmentation was observed using agarose gel electrophoresis and the levels of intracellular ROS and cell cycle progression were measured by flow cytometry.</p></div></div>
<div class="section" id="ajd962-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The levels of cytotoxicity, intracellular ROS, lipid peroxidation and oxidative DNA damage significantly increased after UVB irradiation in the HaCaT cells. UVB irradiation caused pre-G<sub>1</sub>-phase arrest in HaCaT cells and significantly reduced the number of HaCaT cells in the S phase. The GPx mimics 6-CySeCD and 2-phenyl-l,2-benzisoselenazol-3(2H)-one (ebselen) significantly blocked UVB-induced apoptosis and changed the cell cycle of the HaCaT cells. The blocked effect of pretreatment 6-CySeCD in UVB-irradiated HaCaT cells was better than that of pretreatment with ebselen.</p></div></div>
<div class="section" id="ajd962-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>6-CySeCD can relieve the damage induced by UVB irradiation in HaCaT cells.</p></div></div>
]]></content:encoded><description>


Background
The generation of harmful reactive oxygen species (ROS) induced by UVB irradiation could induce cell apoptosis and change the cell cycle. 6A,6A′-dicyclohexylamine-6B,6B′-diselenide-bis-β-cyclodextrin (6-CySeCD) is a novel glutathione peroxidase (GPx; EC 1.11.1.9) mimic. The aim of this study was to investigate the anti-oxidative effects of 6-CySeCD in cultured immortalised human keratinocyte cells (HaCaT).


Methods
HaCaT cells were treated with 30 mJ/cm2 UVB to establish a damage model. The cultured HaCaT cells were randomly assigned to the control, UVB and treatment groups. The treatment group was incubated with 20 μmol/L of GPx mimics before UVB irradiation. Cell viability was detected by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, the level of lipid peroxidation was determined by the formation of malondialdehyde (MDA), DNA fragmentation was observed using agarose gel electrophoresis and the levels of intracellular ROS and cell cycle progression were measured by flow cytometry.


Results
The levels of cytotoxicity, intracellular ROS, lipid peroxidation and oxidative DNA damage significantly increased after UVB irradiation in the HaCaT cells. UVB irradiation caused pre-G1-phase arrest in HaCaT cells and significantly reduced the number of HaCaT cells in the S phase. The GPx mimics 6-CySeCD and 2-phenyl-l,2-benzisoselenazol-3(2H)-one (ebselen) significantly blocked UVB-induced apoptosis and changed the cell cycle of the HaCaT cells. The blocked effect of pretreatment 6-CySeCD in UVB-irradiated HaCaT cells was better than that of pretreatment with ebselen.


Conclusion
6-CySeCD can relieve the damage induced by UVB irradiation in HaCaT cells.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00937.x" xmlns="http://purl.org/rss/1.0/"><title>Eruptive acral naevi following chemotherapy for acute lymphoblastic leukaemia follow typical acral dermoscopic patterns</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00937.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Eruptive acral naevi following chemotherapy for acute lymphoblastic leukaemia follow typical acral dermoscopic patterns</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stephanie Jane Arnold, Jonathan Bowling</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-17T04:39:36.226109-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00937.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00937.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00937.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">DERMOSCOPY</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">126</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">128</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00946.x" xmlns="http://purl.org/rss/1.0/"><title>Exclamation marks and other trichoscopic signs of chemotherapy-induced alopecia</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00946.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Exclamation marks and other trichoscopic signs of chemotherapy-induced alopecia</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rodrigo Pirmez, Juan Piñeiro-Maceira, Celso Tavares Sodré</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-17T21:57:06.142714-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00946.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00946.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00946.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">DERMOSCOPY</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">129</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">132</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00861.x" xmlns="http://purl.org/rss/1.0/"><title>Warfarin-induced calciphylaxis successfully treated with sodium thiosulphate</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00861.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Warfarin-induced calciphylaxis successfully treated with sodium thiosulphate</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Juber Hafiji, Patrick Deegan, Rebecca Brais, Paul Norris</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-16T13:21:03.181319-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00861.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00861.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00861.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">133</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">135</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Calciphylaxis is a rare life-threatening form of skin necrosis. Although traditionally observed in patients with end-stage renal disease and/or hyperparathyroidism, calciphylaxis has also been reported to occur in ‘non-traditional’ patients with normal renal and parathyroid function. We report a case of warfarin-induced calciphylaxis treated successfully with sodium thiosulphate and discuss the role of Vitamin K2 as a potential therapeutic option in the management of warfarin-induced calciphylaxis.</p></div>
]]></content:encoded><description>

Calciphylaxis is a rare life-threatening form of skin necrosis. Although traditionally observed in patients with end-stage renal disease and/or hyperparathyroidism, calciphylaxis has also been reported to occur in ‘non-traditional’ patients with normal renal and parathyroid function. We report a case of warfarin-induced calciphylaxis treated successfully with sodium thiosulphate and discuss the role of Vitamin K2 as a potential therapeutic option in the management of warfarin-induced calciphylaxis.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00866.x" xmlns="http://purl.org/rss/1.0/"><title>Irritant bullous contact dermatitis caused by a rove beetle: An illustrated clinical course</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00866.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Irritant bullous contact dermatitis caused by a rove beetle: An illustrated clinical course</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lindsay McGrath, Peter Piliouras, Ivan Robertson</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-20T14:10:48.067746-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00866.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00866.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00866.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">136</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">138</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>A 26-year-old Australian female traveller in Sierra Leone presented with an irritant bullous contact dermatitis consistent with paederus dermatitis. The lesions were treated with a potent topical corticosteroid with good effect. The affected area resolved in 6 weeks and hyperpigmention persisted for months until complete resolution. This dermatitis occurs when beetles of the genus <em>Paederus</em> (rove beetles) are crushed on the skin, releasing pederin. The same dermatitis ensues with Australian <em>Paederus</em> species. Serial clinical photographs are presented which will aid Australian dermatologists in the diagnosis of this dermatitis, which presents in regional Australian patients and returned overseas travellers.</p></div>
]]></content:encoded><description>

A 26-year-old Australian female traveller in Sierra Leone presented with an irritant bullous contact dermatitis consistent with paederus dermatitis. The lesions were treated with a potent topical corticosteroid with good effect. The affected area resolved in 6 weeks and hyperpigmention persisted for months until complete resolution. This dermatitis occurs when beetles of the genus Paederus (rove beetles) are crushed on the skin, releasing pederin. The same dermatitis ensues with Australian Paederus species. Serial clinical photographs are presented which will aid Australian dermatologists in the diagnosis of this dermatitis, which presents in regional Australian patients and returned overseas travellers.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00926.x" xmlns="http://purl.org/rss/1.0/"><title>Allergic contact dermatitis to indium in jewellery: diagnosis made possible through the use of the Contact Allergen Bank Australia</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00926.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Allergic contact dermatitis to indium in jewellery: diagnosis made possible through the use of the Contact Allergen Bank Australia</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sarah E Gamboni, Ivan Simmons, Amanda Palmer, Rosemary L Nixon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-26T02:20:29.838921-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00926.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00926.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00926.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">139</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">140</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We report a case of a 39-year-old woman from Adelaide who developed allergic contact dermatitis to the rare allergen indium in her ring. The allergen was sourced for patch testing using the Contact Allergen Bank Australia (CABA), based at the Skin and Cancer Foundation in Melbourne, and posted to Adelaide. This case illustrates the usefulness of CABA in facilitating patch testing throughout Australia, especially when rare allergens are involved.</p></div>
]]></content:encoded><description>

We report a case of a 39-year-old woman from Adelaide who developed allergic contact dermatitis to the rare allergen indium in her ring. The allergen was sourced for patch testing using the Contact Allergen Bank Australia (CABA), based at the Skin and Cancer Foundation in Melbourne, and posted to Adelaide. This case illustrates the usefulness of CABA in facilitating patch testing throughout Australia, especially when rare allergens are involved.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12033" xmlns="http://purl.org/rss/1.0/"><title>Intravascular metastatic melanoma: A difficult diagnosis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12033</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Intravascular metastatic melanoma: A difficult diagnosis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Samer Ghattas, Julie Howle, Wei Wang, Richard Kefford, Simon Gruenewald</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T00:50:21.028387-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12033</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12033</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12033</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">141</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">143</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Melanoma is a common cancer with the potential for widespread metastasis; however intravascular metastasis is extremely rare. We report an unusual case of a patient with metastatic melanoma in whom <sup>18</sup>F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) demonstrated an intravascular melanoma metastasis in the superior vena cava (SVC), successfully treated with external beam radiotherapy. To our knowledge, this is the first reported case where FDG PET-CT was used to make this diagnosis.</p></div>
]]></content:encoded><description>

Melanoma is a common cancer with the potential for widespread metastasis; however intravascular metastasis is extremely rare. We report an unusual case of a patient with metastatic melanoma in whom 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) demonstrated an intravascular melanoma metastasis in the superior vena cava (SVC), successfully treated with external beam radiotherapy. To our knowledge, this is the first reported case where FDG PET-CT was used to make this diagnosis.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00936.x" xmlns="http://purl.org/rss/1.0/"><title>Toxic epidermal necrolysis caused by over the counter eyedrops</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00936.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Toxic epidermal necrolysis caused by over the counter eyedrops</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lisa Byrom, Tania Zappala, Jim Muir</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-17T04:38:56.989076-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2012.00936.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2012.00936.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2012.00936.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">144</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">146</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We present a case of a 15-year-old boy who developed toxic epidermal necrolysis (TEN) from sulfacetamide eyedrops. He presented with conjunctival injection and an erythematous rash that rapidly progressed to epidermal necrosis of over 30% of his body. A skin biopsy revealed an acute lichenoid reaction pattern consistent with TEN. After 22 days in hospital, he was left with significant scarring to his eyes, mouth and anogenital areas. An extensive search for an infective aetiology was negative. Previously exposed to bactrim tablets, he used Bleph-10 eyedrops 3 days before admission to hospital. The patient had a strong family history of sulphur allergy. The onset of TEN after topical administration of medication has been reported rarely in the literature. This case highlights the need for a thorough medication history that includes topical preparations.</p></div>
]]></content:encoded><description>

We present a case of a 15-year-old boy who developed toxic epidermal necrolysis (TEN) from sulfacetamide eyedrops. He presented with conjunctival injection and an erythematous rash that rapidly progressed to epidermal necrosis of over 30% of his body. A skin biopsy revealed an acute lichenoid reaction pattern consistent with TEN. After 22 days in hospital, he was left with significant scarring to his eyes, mouth and anogenital areas. An extensive search for an infective aetiology was negative. Previously exposed to bactrim tablets, he used Bleph-10 eyedrops 3 days before admission to hospital. The patient had a strong family history of sulphur allergy. The onset of TEN after topical administration of medication has been reported rarely in the literature. This case highlights the need for a thorough medication history that includes topical preparations.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12050" xmlns="http://purl.org/rss/1.0/"><title>Letter to the Editor</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12050</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Letter to the Editor</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shreya Dixit, Stephen Shumack, Gayle Fischer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-14T20:41:24.851886-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12050</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12050</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12050</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">LETTER TO THE EDITOR</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">147</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">147</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12014" xmlns="http://purl.org/rss/1.0/"><title>Treatment goals for moderate to severe psoriasis: An Australian consensus</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12014</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Treatment goals for moderate to severe psoriasis: An Australian consensus</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christopher Baker, Alexandra Mack, Alan Cooper, Gayle Fischer, Stephen Shumack, Shireen Sidhu, Peter Soyer, Jason Wu, Jonathan Chan, Peter Nash, Morton Rawlin, Barbara Radulski, Peter Foley</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-18T01:11:28.529194-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12014</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12014</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12014</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">CONSENSUS ARTICLE</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">148</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">154</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="ajd12014-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background/Objectives</h4><div class="para"><p>The high incidence of comorbidities in patients with psoriasis, significant impact on quality of life and patients' dissatisfaction with treatment led a European group to develop a consensus position on psoriasis treatment goals. There is an evident need for similar treatment goals in Australia. The aim of this project was to develop Australian treatment goals that reflect the local environment.</p></div></div>
<div class="section" id="ajd12014-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A panel of 12 representatives was drawn from across Australia consisting of nine dermatologists and a rheumatologist, a dermatology nurse and a general practitioner (GP)/dermatology trainee. The group met on three occasions between September 2011 and March 2012. The panel undertook a literature review and critically examined available evidence-based treatment goals. A questionnaire relating to psoriasis assessment and specific treatment outcomes was developed. Following discussion and debate, recommended treatment goals for psoriasis patients in Australia were determined.</p></div></div>
<div class="section" id="ajd12014-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The panel agreed by consensus on recommended psoriasis treatment goals in the Australian environment. There was recognition that in addition to psoriasis area severity index (PASI) assessment, a quality of life assessment was highly relevant in determining psoriasis severity and treatment outcome. Mild psoriasis was defined as PASI ≤ 10 and a dermatology life quality index (DLQI) ≤ 10, with moderate to severe psoriasis defined as PASI &gt; 10 and/or DLQI &gt; 10. The presence of certain definedclinical features would elevate a patient's classification from mild to moderate/severe. The target for treatment was defined as a maintained change in PASI ≥ 75% improvement and DLQI ≤ 5. These largely concurred with the European treatment goals. A flow chart for psoriasis management in Australia based on outcome measures was developed.</p></div></div>
<div class="section" id="ajd12014-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>There is a need to identify and articulate treatment goals for psoriasis. Assessment of psoriasis severity requires both physical scoring (PASI) and consideration of quality of life measures (DLQI). Identification of treatment goals will guide clinicians in treatment decision-making, enhance the availability and appropriate use of therapies and increase patient satisfaction with their care.</p></div></div>
]]></content:encoded><description>


Background/Objectives
The high incidence of comorbidities in patients with psoriasis, significant impact on quality of life and patients' dissatisfaction with treatment led a European group to develop a consensus position on psoriasis treatment goals. There is an evident need for similar treatment goals in Australia. The aim of this project was to develop Australian treatment goals that reflect the local environment.

 Methods
A panel of 12 representatives was drawn from across Australia consisting of nine dermatologists and a rheumatologist, a dermatology nurse and a general practitioner (GP)/dermatology trainee. The group met on three occasions between September 2011 and March 2012. The panel undertook a literature review and critically examined available evidence-based treatment goals. A questionnaire relating to psoriasis assessment and specific treatment outcomes was developed. Following discussion and debate, recommended treatment goals for psoriasis patients in Australia were determined.


Results
The panel agreed by consensus on recommended psoriasis treatment goals in the Australian environment. There was recognition that in addition to psoriasis area severity index (PASI) assessment, a quality of life assessment was highly relevant in determining psoriasis severity and treatment outcome. Mild psoriasis was defined as PASI ≤ 10 and a dermatology life quality index (DLQI) ≤ 10, with moderate to severe psoriasis defined as PASI &gt; 10 and/or DLQI &gt; 10. The presence of certain definedclinical features would elevate a patient's classification from mild to moderate/severe. The target for treatment was defined as a maintained change in PASI ≥ 75% improvement and DLQI ≤ 5. These largely concurred with the European treatment goals. A flow chart for psoriasis management in Australia based on outcome measures was developed.


Conclusions
There is a need to identify and articulate treatment goals for psoriasis. Assessment of psoriasis severity requires both physical scoring (PASI) and consideration of quality of life measures (DLQI). Identification of treatment goals will guide clinicians in treatment decision-making, enhance the availability and appropriate use of therapies and increase patient satisfaction with their care.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12060" xmlns="http://purl.org/rss/1.0/"><title>Erratum</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12060</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Erratum</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-14T20:41:24.851886-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/ajd.12060</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/ajd.12060</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajd.12060</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">ERRATUM</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">155</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">155</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00827.x" xmlns="http://purl.org/rss/1.0/"><title>Neuropathy in a patient with lymphocytic thrombophilic arteritis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00827.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Neuropathy in a patient with lymphocytic thrombophilic arteritis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sarah Shen, Richard A Williams, Robert I Kelly</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-06T12:21:55.213136-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00827.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00827.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00827.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">CASE REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e28</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e32</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>A 35-year-old Lebanese woman presented with a 3-year history of persistent, localized livedo racemosa over her feet, distal legs and forearms that was associated with the development of lower limb sensorimotor neuropathy. Investigations revealed the patient was heterozygous for prothrombin gene mutation and was also found to have a T-cell receptor gamma chain gene rearrangement. Histological examination revealed a mid-lower dermal medium vessel lymphocytic vasculitis with prominent fibrinoid ring within its wall. These findings are consistent with a recently described condition known as lymphocytic thrombophilic arteritis. This has so far been considered to be a benign clinical condition not associated with extra cutaneous manifestations. The novel findings in the present case are the associated sensorimotor neuropathy and the characteristic fibrin ring appears to be intramural rather intraluminal in location. The findings of a T cell gene rearrangement and a prothombin gene mutation suggest that both immunological and thrombophilic factors might contribute to the development of this condition.</p></div>
]]></content:encoded><description>

A 35-year-old Lebanese woman presented with a 3-year history of persistent, localized livedo racemosa over her feet, distal legs and forearms that was associated with the development of lower limb sensorimotor neuropathy. Investigations revealed the patient was heterozygous for prothrombin gene mutation and was also found to have a T-cell receptor gamma chain gene rearrangement. Histological examination revealed a mid-lower dermal medium vessel lymphocytic vasculitis with prominent fibrinoid ring within its wall. These findings are consistent with a recently described condition known as lymphocytic thrombophilic arteritis. This has so far been considered to be a benign clinical condition not associated with extra cutaneous manifestations. The novel findings in the present case are the associated sensorimotor neuropathy and the characteristic fibrin ring appears to be intramural rather intraluminal in location. The findings of a T cell gene rearrangement and a prothombin gene mutation suggest that both immunological and thrombophilic factors might contribute to the development of this condition.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00847.x" xmlns="http://purl.org/rss/1.0/"><title>Eccrine angiomatous hamartoma causing walking difficulties</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00847.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Eccrine angiomatous hamartoma causing walking difficulties</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shuang Chen, Lin Xiong, Sheng Wang, Ting-Ting Wang, Lin Wang, Dilip Gurung</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T06:08:28.748003-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00847.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00847.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00847.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">CASE REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e33</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e36</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Eccrine angiomatous hamartoma (EAH) is a rare tumoral lesion that consists of vascular and eccrine malformation and often occurs in the distal extremities of children. Although EAH is benign, a therapeutic excision may be required for symptomatic or cosmetic considerations. We hereby report a typical case of EAH presenting as a painful and rapidly growing plaque on the right thigh. The associated symptoms of pain, hyperhidrosis and local hypertrichosis caused walking difficulties until the patient was cured by two excisional surgeries.</p></div>
]]></content:encoded><description>

Eccrine angiomatous hamartoma (EAH) is a rare tumoral lesion that consists of vascular and eccrine malformation and often occurs in the distal extremities of children. Although EAH is benign, a therapeutic excision may be required for symptomatic or cosmetic considerations. We hereby report a typical case of EAH presenting as a painful and rapidly growing plaque on the right thigh. The associated symptoms of pain, hyperhidrosis and local hypertrichosis caused walking difficulties until the patient was cured by two excisional surgeries.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00826.x" xmlns="http://purl.org/rss/1.0/"><title>Acroangiodermatitis in a lower leg amputee related to suction socket use</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00826.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Acroangiodermatitis in a lower leg amputee related to suction socket use</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paul Armenores, Craig L James, Warren Weightman, Shyamala C Huilgol</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-15T22:10:58.876676-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00826.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00826.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00826.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e37</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e39</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Acroangiodermatitis is a rare condition with numerous causes typically presenting as purple macules on the lower extremities. Although benign, it can mimic the presentation of more serious underlying conditions such as Kaposi's sarcoma. We present a case of acroangiodermatitis in the stump of an amputee related to suction socket use in order to raise awareness of an unusual setting for this vascular proliferation.</p></div>
]]></content:encoded><description>

Acroangiodermatitis is a rare condition with numerous causes typically presenting as purple macules on the lower extremities. Although benign, it can mimic the presentation of more serious underlying conditions such as Kaposi's sarcoma. We present a case of acroangiodermatitis in the stump of an amputee related to suction socket use in order to raise awareness of an unusual setting for this vascular proliferation.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00865.x" xmlns="http://purl.org/rss/1.0/"><title>A rare cutaneous presentation of metastatic parotid adenocarcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00865.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A rare cutaneous presentation of metastatic parotid adenocarcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Juber Hafiji, Edward Rytina, Piyush Jani, Nigel P Burrows</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-03-02T14:01:46.605128-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00865.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00865.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00865.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e40</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e42</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Primary adenocarcinomas of the parotid gland are rare, accounting for &lt; 5% of all head and neck malignant neoplasms. The biological behaviour of these tumours varies considerably. Low-grade tumours are minimally invasive, whereas high-grade tumours show a high incidence of local recurrence and distant metastases. We report a case of metastatic parotid adenocarcinoma which presented with cutaneous features. This case illustrates that such salivary gland malignancies can very rarely present to the dermatologist. These potentially aggressive tumours require prompt diagnosis and management with multidisciplinary team input to ensure that the appropriate treatment is instigated.</p></div>
]]></content:encoded><description>

Primary adenocarcinomas of the parotid gland are rare, accounting for &lt; 5% of all head and neck malignant neoplasms. The biological behaviour of these tumours varies considerably. Low-grade tumours are minimally invasive, whereas high-grade tumours show a high incidence of local recurrence and distant metastases. We report a case of metastatic parotid adenocarcinoma which presented with cutaneous features. This case illustrates that such salivary gland malignancies can very rarely present to the dermatologist. These potentially aggressive tumours require prompt diagnosis and management with multidisciplinary team input to ensure that the appropriate treatment is instigated.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00848.x" xmlns="http://purl.org/rss/1.0/"><title>Blastic plasmacytoid dendritic cell neoplasm</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00848.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Blastic plasmacytoid dendritic cell neoplasm</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Lim, Hugh Goodman, Marius Rademaker, Duncan Lamont, Anthony Yung</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:23:29.615662-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00848.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00848.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00848.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e43</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e45</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy that originates from the precursors of plasmacytoid dendritic cells. It commonly presents with findings isolated to the skin although it usually progresses to a leukaemic phase. It has a poor prognosis but is curable, particularly in younger patients treated with allogeneic bone marrow transplantation. We report a case of a 79-year old man who had 6 months of progressive, asymptomatic BPDCN manifestations limited to the skin, before developing a leukaemic phase.</p></div>
]]></content:encoded><description>

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy that originates from the precursors of plasmacytoid dendritic cells. It commonly presents with findings isolated to the skin although it usually progresses to a leukaemic phase. It has a poor prognosis but is curable, particularly in younger patients treated with allogeneic bone marrow transplantation. We report a case of a 79-year old man who had 6 months of progressive, asymptomatic BPDCN manifestations limited to the skin, before developing a leukaemic phase.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00857.x" xmlns="http://purl.org/rss/1.0/"><title>Recurrent endocrine mucin-producing sweat gland carcinoma in the eyelid</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00857.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Recurrent endocrine mucin-producing sweat gland carcinoma in the eyelid</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tomoyuki Koike, Taro Mikami, Jiro Maegawa, Toshinori Iwai, Hidefumi Wada, Shoji Yamanaka</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-19T05:22:23.815457-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00857.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00857.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00857.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e46</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e49</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Endocrine mucin-producing sweat gland carcinoma (EMPSGC) has recently been recognised as a low-grade carcinoma that almost always occurs on the eyelid. This carcinoma is very rare, with only 20 cases (including the present one) having been reported in the literature. EMPSGC is frequently found in association with invasive mucinous carcinoma. While EMPSGC treatments consist of a complete surgical removal, there has been no consensus regarding the surgical margin. Therefore, reports on surgical management of EMPSGC may potentially provide important therapeutic information. Here, we present a case of a 74-year-old man with EMPSGC of the eyelid that repeatedly recurred despite surgical treatments at another institution. After referral to our department, the patient underwent tumour excision. However, the specimen revealed a positive surgical margin and thus, he subsequently underwent a wider excision. There has been no sign of tumour recurrence or metastasis 6 months after his last operation. This article reviews the current literature and discusses the surgical management of EMPSGC.</p></div>
]]></content:encoded><description>

Endocrine mucin-producing sweat gland carcinoma (EMPSGC) has recently been recognised as a low-grade carcinoma that almost always occurs on the eyelid. This carcinoma is very rare, with only 20 cases (including the present one) having been reported in the literature. EMPSGC is frequently found in association with invasive mucinous carcinoma. While EMPSGC treatments consist of a complete surgical removal, there has been no consensus regarding the surgical margin. Therefore, reports on surgical management of EMPSGC may potentially provide important therapeutic information. Here, we present a case of a 74-year-old man with EMPSGC of the eyelid that repeatedly recurred despite surgical treatments at another institution. After referral to our department, the patient underwent tumour excision. However, the specimen revealed a positive surgical margin and thus, he subsequently underwent a wider excision. There has been no sign of tumour recurrence or metastasis 6 months after his last operation. This article reviews the current literature and discusses the surgical management of EMPSGC.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00875.x" xmlns="http://purl.org/rss/1.0/"><title>Co-existence of hereditary coproporphyria and porphyria cutanea tarda: The importance of genetic testing</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00875.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Co-existence of hereditary coproporphyria and porphyria cutanea tarda: The importance of genetic testing</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alice Rudd, Janine Grant, George Varigos, Vanessa Morgan, Ingrid Winship</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-03-21T13:25:36.69037-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00875.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00875.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00875.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e50</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e52</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The porphyrias are a group of inherited disorders that result in defects in the enzymes of the haem biosynthetic pathway, causing photosensitive bullous skin eruptions or abdominal and neurological attacks. Enzymatic defects result in specific porphyrin excretory patterns that are diagnosed biochemically and can be confirmed by genetic testing. Defects in the coproporphyrinogen oxidase (CPOX) enzyme result in the autosomal dominant hereditary coproporphyria. Multiple mutations have been identified in the CPOX gene and incomplete penetrance is noted. Latent carriers without clinical evidence of disease are at risk of life-threatening attacks. Porphyria cutanea tarda may be inherited, but is more commonly acquired. Occasionally two forms of porphyria may co-exist. The importance of genetic testing is discussed.</p></div>
]]></content:encoded><description>

The porphyrias are a group of inherited disorders that result in defects in the enzymes of the haem biosynthetic pathway, causing photosensitive bullous skin eruptions or abdominal and neurological attacks. Enzymatic defects result in specific porphyrin excretory patterns that are diagnosed biochemically and can be confirmed by genetic testing. Defects in the coproporphyrinogen oxidase (CPOX) enzyme result in the autosomal dominant hereditary coproporphyria. Multiple mutations have been identified in the CPOX gene and incomplete penetrance is noted. Latent carriers without clinical evidence of disease are at risk of life-threatening attacks. Porphyria cutanea tarda may be inherited, but is more commonly acquired. Occasionally two forms of porphyria may co-exist. The importance of genetic testing is discussed.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00874.x" xmlns="http://purl.org/rss/1.0/"><title>Lupus vulgaris: Difficulties in diagnosis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00874.x</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Lupus vulgaris: Difficulties in diagnosis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julia Rhodes, Tony Philip Caccetta, Clare Tait</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-23T13:26:56.606149-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1111/j.1440-0960.2011.00874.x</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1111/j.1440-0960.2011.00874.x</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fj.1440-0960.2011.00874.x</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">BRIEF REPORT</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e53</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">e55</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Lupus vulgaris is one of the most common forms of cutaneous tuberculosis. It presents a diagnostic challenge due to its paucibacillary nature. This is a report of a case of a delayed diagnosis of lupus vulgaris, presenting as perianal and peristomal plaques, followed by a review of the diagnostic tools for lupus vulgaris and their limitations.</p></div>
]]></content:encoded><description>

Lupus vulgaris is one of the most common forms of cutaneous tuberculosis. It presents a diagnostic challenge due to its paucibacillary nature. This is a report of a case of a delayed diagnosis of lupus vulgaris, presenting as perianal and peristomal plaques, followed by a review of the diagnostic tools for lupus vulgaris and their limitations.
</description></item></rdf:RDF>